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Abstract
Current immunotherapies are only effective in a fraction of cancer patients. One of the
main contributing factors to therapy resistance and overall poor prognosis is the immune status
of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) have been shown
to have significant influence on the immune status of the TME. As key players in maintaining tissue homeostasis, macrophages exhibit a broad range of phenotypes and functions, making TAMs a
promising target for immunomodulatory therapies. As liaisons between innate and adaptive immunity, TAMs can promote a robust anti-tumor response involving both innate and adaptive immunity.
This study investigated the potential of a phagocytic-directed immunomodulatory therapy via zymosan conjugated recombinant adenoviruses encoding constant active forms of interferon regulatory
factor 3 (IRF3) and 7 (IRF7), which have been shown to induce a pro-inflammatory, anti-tumor
phenotype in TAMs. Conjugation of these recombinant adenoviruses to zymosan particles altered
their natural tropism to become targets for phagocytic cells. Derived from the cell wall of yeast,
biodegradable zymosan particles can induce pro-inflammatory, anti-tumor responses to some extent
due to β-glucans, a known pathogen associated molecular pattern (PAMP). Recombinant adenovirus
can also activate pro-inflammatory signaling pathways in host cells. The overall goal of this conjugation was to not only target phagocytic cells but also to generate a synergistic activation signal
for pro-inflammatory pathways within the targeted cells. First, this study evaluated the potential
of these zymosan-adenovirus conjugate particles to alter TAM phenotype in vitro. The zymosanadenovirus conjugate particles, regardless of encoding IRF3 or IRF7, induced a shift from M2-like to
M1-like phenotype in TAM-like BMDMs in vitro as determined by changes in relative gene expression, cytokine secretion, and transcription factor expression. Of note, zymosan-adenovirus particles
increased IL-12 and decreased IL-10, signature cytokines of M1/Th1 and M2/Th2 responses, respectively. Further, M1 transcription factor expression of pSTAT1 and pNF-κBp65 increased. These
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findings prompted further investigation of the zymosan-adenovirus conjugates as immunomodulatory
therapies in vivo in a B16 melanoma double tumor mouse model via intratumoral injection. The
TME, which consists of tumor cells, non-tumor stromal cells, immune cells (e.g., macrophages and
lymphocytes), and non-cellular components of the extracellular matrix, poses a significant challenge
for current immunotherapies. By manipulating the function of cellular and non-cellular components
via complex signaling pathways, tumor cells either attract suppressive regulatory cell subtypes or
coerce or suppress non-malignant cells to form an immunosuppressive environment. It has been
suggested that intratumoral injection of immunomodulatory agents could elicit a non-tumor specific
strong immune response within the TME, which in turn creates a favorable environment to ensure
subsequent tumor specific antigen presentation and T cell activation to generate cytotoxic CD8 T
cells and to form long-term anti-tumor memory responses. In this study, alterations in the immune
status of the TME were determined by analysis of TAM phenotype, cytokine and chemokine gene
expression, metabolic gene expression, and T cell specific gene expression. TAMs sorted using flow
cytometry indicated downregulation of M2-like TAMs, CD11b+ F4/80+ CD206+ , and upregulation
of M1-like TAMs, CD11b+ F4/80+ CD80+ . Downregulation of Arg1 and upregulation of Irg1 gene
expression suggested a potential shift toward an M1-like metabolic state, which was further supported by upregulation of IFNγ, Trail, and IL-12 and downregulation of CXCL1, CXCL2, and MIF
in the TME. A snapshot of lymphocyte composition was derived from tumor tissue gene expression data suggesting an upregulation in CD3, CD4, and CD8 gene expression following all three
zymosan-adenovirus treatments. Together, findings suggested that the zymosan-adenovirus particles contributed to upregulation of immune favorable conditions in the TME. Further, induction of
systemic tumor immunity was determined by untreated tumor analysis in the double tumor model
as well as a splenocyte proliferation assay. Zymosan-adenovirus treatments reduced tumor growth in
untreated tumors and their splenocytes displayed enhanced B16 specific lysis. Lastly, constant active
IRF3 enhanced zymosan-adenovirus anti-tumor activity as determined by significant reduction in tumor growth of both treated and untreated tumors. Taken together, this work supports the potential
of the zymosan-adenovirus encoding constant active IRF3 as an intratumoral immunomodulatory
therapy in combination with immune checkpoint inhibitors.
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Chapter 1

Introduction
1.1

Immunotherapy Overview
The beginning of cancer immunotherapy dates back to William B. Coley, the ”Father of

Cancer Immunotherapy” in the late 1800s who injected live streptococci, known as Coley’s Toxins
into sarcoma patients and observed favorable responses [Waldman et al., 2020]. Now there are two
broad categories of immunotherapy including passive immunotherapy, targeting tumor cells rather
than immune cells (e.g., tumor-specific monoclonal antibodies), and active immunotherapy, stimulating antigen presenting cells and T cells via specific or non-specific methods (e.g., therapeutic
vaccines) with a goal of induces systemic tumor immunity. The most common types of immunotherapy used today include therapeutic vaccines, antibody complexes, adoptive immune cell transfer,
and immunomodulatory agents. Therapeutic vaccines have been developed to take advantage of
tumor-associated antigens or act as general immune stimulants. Monoclonal antibodies, antibodydrug complexes, and bispecific antibodies are used to disrupt pathways and activate immune cells.
Adoptive immune cell therapy allows oncologists and researchers to isolate immune cells (e.g., T
cells, dendritic cells) from patients, re-engineer their receptors, and reintroduce them to patients
for more potent tumor cytotoxicity. Oncolytic viruses are created by modifying viruses (such as
HSV) to infect tumor cells and stimulate an immune response. The most recent breakthrough
involves, immune checkpoint blockades. Antibodies block these immune checkpoint receptors on
immune cells or the ligands on tumor cells preventing tumor cells from deactivating CD8 T cells.
Yet, immunotherapy is only effective in 15-20% of cancer patients. The focus of this research is on
1

the impact that the immune status has on immunotherapy efficacy; however, there are many other
factors that contribute (e.g., tumor mutational burden, lack of expression of PD-L1 on tumor cells).

1.1.1

Immunomodulatory Therapies
Several potent immunotherapies (cancer vaccines, CAR-T cell therapy, immune checkpoint

inhibitors, oncolytic viruses, and targeted antibodies) are only effective in a fraction of patients due to
resistance attributed to an immunosuppressive tumor microenvironment (TME) [Tang et al., 2016].
Immunomodulatory agents, such as cytokines and PRR agonists, alter the immune status of the
TME and have been shown to induce immune favorable conditions in the tumor microenvironment
[Locy et al., 2018].
CAR-T cell therapy is an effective treatment for lymphoma and other B cell related malignancies; however, this efficacy does not translate to solid tumors, most likely due to a lack of
or suppressed TILs in the TME [Sterner and Sterner, 2021]. Combining CAR-T cell therapy with
immunomodulatory agents, such as interleukin-12 (IL-12) has been shown to enhance therapeutic
efficacy in solid tumors [Koneru et al., 2015]. Further, reducing anti-inflammatory cytokine expression, such as IL-4, in the TME also leads to increased efficacy of CAR-T cell therapy [Mohammed
et al., 2017].
Similarly, the efficacy of checkpoint inhibitors is limited by an immunosuppressive milieu
including regulatory T cells (Tregs), M2-like tumor associated macrophages (TAMs), and myeloid
derived suppressor cells (MDSCs) that secrete anti-inflammatory cytokines and can inhibit infiltration of CD8 T cells. Combining passive immunotherapy, such as administration of type I interferons
(IFNs), or active immunotherapy, such as toll-like receptor (TLR) agonists, has been shown to
improve response to immune checkpoint inhibitors. Administration of IFNα, associated with antitumor effects in the TME and clinical benefits, from immunotherapies improved objective responses
in PD-1 blockade therapy in advanced melanoma patients [Davar et al., 2018].
An effective therapeutic vaccine increases uptake of tumor associated antigens or neoantigens by professional antigen presenting cells, enhances antigen processing and presenting, and
recruits CD4 and CD8 T cells to the tumor. Therapeutic cancer vaccines are limited by the immune
status of the TME, thus making them more attractive for use in combination therapies. Specifically,
supplementing peptide vaccines with immunostimulating agents, such as pro-inflammatory cytokine
interleukin-2 (IL-2), has been shown to improve progression-free and overall survival of a gp100
2

peptide vaccine in metastatic melanoma patients [Schwartzentruber et al., 2011].
An effective immunotherapy needs to reverse the immunosuppressive TME by increasing
lymphocyte infiltration and activation, decreasing tumor promoting cytokines, and increasing antitumor cytokines. Although delivery of cytokines increases efficacy of many immunotherapies, the
half-life of cytokines is short thus limiting its potency [Berraondo et al., 2018]. Instead of supplementing these current immunotherapies with cytokines, pathogen-associated molecular patterns
(PAMPs) and damage-associated molecular patterns (DAMPs), which stimulate a pro-inflammatory,
anti-tumor response via stimulation of pathogen recognition receptors (PRRs) can trigger production
of a natural more potent cocktail of beneficial cytokines and chemokines [Li et al., 2017a].
One family of PRRs, TLRs, have been the target for adjuvant therapies in many solid cancers
due to their elicitation of a strong anti-tumor immune response when activated in phagocytic cells
such as macrophages and dendritic cells. However, TLRs are not unique to immune cells resulting in
off-target uptake which decreases its potency and increases potential for adverse effects. Specifically,
TLR4 agonists have been found to induce tumor growth when taken up by tumor cells, but specific
activation of TLR4 pathway in antigen presenting cells has been shown to augment anti-tumor
immune responses in the TME [Liu et al., 2020].
To prevent off-target effects and enhance the anti-tumor effects of PAMPs and DAMPs, targeted activation of PRR pathways in phagocytic cells have shown potential. This research focuses on
eliciting a pro-inflammatory response in tumor associated macrophages (TAMs). TAMs are highly
plastic, diverse in function, and have been implicated in both immunosuppression and immune activation in solid cancers. Skewing TAMs to an immune active M1-like phenotype could increase their
cytostatic activity against tumor cells, enhance their ability for tumor antigen cross-presentation,
and more importantly, produce more immunostimulating cytokines for T cell activation, which could
potentially reduce tumor progression and enhance immunotherapy efficacy.

1.1.2

The Rise of Immunomodulatory Intratumoral Injections
Systemic tumor therapeutic vaccination via intravenous (IV), subcutaneous (SC), intrader-

mal (ID), or intramuscular (IM) injection results in antigen presenting cell activation and subsequent
migration to lymph node for antigen presentation. While direct administration of immunostimulants
into the tumor mileu is to create an immune active TME to allow in situ presentation of various
tumor antigens from dead tumor cells, which will elicit and potentiate tumor-specific immune re3

sponses. There are benefits and challenges of each type of administration, this section specifically
focuses on comparing IV and intratumoral (IT) administration in the context of cancer therapeutic
vaccines.
Classic therapeutic cancer vaccines are defined by their ability to invoke tumor associated
antigen (TAA) uptake by APCs, followed by effective processing or cross-presenting of the TAAs
to CD8+ T cells. The challenges of classic therapeutic cancer vaccines include identifying tumor
associated antigens, overcoming immunosuppression in the TME, and inducing systemic toxicity. An
alternative approach is to directly administer IT immunodulatory therapies, which can be used in
combination with cancer vaccines or as monotherapies. IT immunomodulatory therapies overcome
each of the challenges posed by classic therapeutic vaccines; however, the practicality of IT injections
is still a clinical challenge for a broad range of solid tumors.
First, classic administration of cancer vaccines requires patient-specific identification and
customization of neoantigens or TAAs. TAAs vary from patient to patient and tumor to tumor,
thus creating a challenge for vaccine production and cost due to the need for personalized medicine.
IT immunodulatory therapies do not require TAAs because they can directly induce apoptosis in
tumor cells, allowing for APCs to cross-present TAAs directly from the apoptotic tumor cells without
identifying and generating TAAs ex vivo.
Activated APCs cross-present the TAAs to CD8 T cells in nearby lymph nodes leading to
circulation of anti-tumor CD8 T cells. Depending on the immune status of the TME, CD8 T cells may
be blocked from infiltrating or deactivated upon infiltration of the tumor. IT immunomodulatory
therapies circumvent this problem because the milieu of the TME is directly altered to an immune
active state thus reducing suppressive immune cells and cytokines that can lead to CD8 T cell
deactivation and by increasing metabolites required for CD8 T cell function.
Cancer vaccine dosage needs to be kept relatively low to prevent systemic toxicities. Dose
escalation studies allow researchers to find the optimal dose without inducing detrimental toxicities,
thus limiting the anti-tumor potential of the vaccine. IT administration typically has reduced
systemic toxicity, which can be attributed to smaller drug amounts and less accumulation of drugs
in non-tumor tissue. In summary IT administration allows for a significantly reduced dosage while
still inducing a potent localized and systemic anti-tumor response.
One of the biggest challenges of IT immunomodulatory therapies is the practicality of physically delivering the therapy to deep solid tumors. IT injections are common for skin cancer due to
4

easy access with needles, but many solid tumors cannot be reached via routine needle injection. However, advances in medical procedures and surgeries allow for minimally invasive access to a broader
range of solid tumors via alternative methods. For instance, image-guiding technology can allow for
direct injection into colon, lung, and ovarian tumors [Marabelle et al., 2018]. Although injectibility
is still a challenge, we now have the technology to explore the potential to induce a strong systemic
anti-tumor response with minimal off-target, systemic toxicity of direct intratumoral therapies in a
broader range of solid tumors [Locy et al., 2018].
Efficacy of IT immunomodulatory therapies are often evaluated using double tumor models involving simultaneous inoculation or a re-challenge approach. In simultaneous double tumor
models, mice are simultaneously inoculated with the same number of tumor cells, usually subcutaneously in the left and right abdomen, and the IT therapy in question is administered to one of the
two tumors. The untreated tumor can be assessed for growth as well as analysis of tumor tissue
to determine anti-tumor activity and changes in immune status of the TME allowing for objective
evaluation of systemic immune response [Houot and Levy, 2009]. The re-challenge double tumor
model requires longer studies and provides robust analysis of therapy efficacy. [Wang et al., 2018].
Following inoculation, treatment, and regression of initial tumors, mice are re-challenged via inoculation with the same type of cancer as the first inoculation. If successful, mice can be challenged
again with an unfamiliar type of cancer to confirm a cancer-specific immune response. In summary,
IT immunomodulatory therapies are promising as monotherapies or to boost immunotherapies that
rely on an immune active TME.

1.1.3

Types of Immune Tumor Microenvironments
As tumor cells progressively become more oncogenic, they influence changes in the surround-

ing tissue, cellular and non-cellular components, that lead to a distinct and abnormal environment
known as the tumor microenvironment (TME). The TME consists of dynamic crosstalk and interactions between tumor cells, non-tumor cells (e.g., stromal cells and immune cells), and non-cellular
components (e.g., ECM, cytokines, chemokines, growth factors, etc.) and thus plays a vital role in
cancer progression and therapeutic resistance [Wang et al., 2017]. The TME can be sub-classified
into several distinct microenvironments or niches including hypoxic niches, immune microenvironment, metabolism microenvironment, mechanical microenvironment, innervated niches, and acidic
niches that each play a role in tumor progression and therapy resistance [Jin and Jin, 2020]. This
5

section focuses on the immune component of the TME and the establishment and implications of
an immunosuppressive TME.

Figure 1.1: Tumor and Immune Interactions (adapted from Biorender.com)

The immune profile of the TME varies from tumor to tumor and within different regions of
the tumor, and the overall immunological state of the TME is often used as an indicator of clinical
outcome [Binnewies et al., 2018, Jorge et al., 2020]. In early stages of tumor development, the
immune composition of the tumor microenvironment tends to have a Th1 profile (Figure 1.1). This
includes natural killer T type 1 (NKT1) cells, natural killer type 1 (NK1) cells, innate lymphoid
cells type 1 (ILC1), Th1 CD4 T cells, cytotoxic CD8 T cells, M1 macrophages, N1 neutrophils, and
dendritic cells (DCs). Th1 CD4 T cells produce IL-1β, IL-2, IL-12, TNF-α, and IFN-γ, which all
promote a pro-inflammatory response and thus are associated with good prognosis in many solid
cancers [Saillard et al., 2021]. Further CD4 T cells both directly and indirectly assist in anti-tumor
CD8 T cell activation, they have direct anti-tumor activity via secretion of cytokines (e.g., TNFα and IFN-γ), and they interact with B cells to assist in anti-tumor antibody production [Tay
et al., 2021]. NKT1 cells are a group of specialized T cells that have both innate and adaptive
characteristics and are particularly important in sensing changes in lipid metabolism via MHCI
lipid antigen presentation [Nair and Dhodapkar, 2017]. Cytotoxic CD8 T cells may be one of the
most well studied immune cells in the tumor microenvironment. The majority of immunotherapies
are designed to induce or take advantage of their anti-tumor specificity and potency. Their full
activation typically involves three signals including activation of the T-cell receptor (TCR), co6

stimulatory receptor activation (e.g., PD-l, CTLA-4), and exposure to pro-inflammatory cytokines
(e.g., IL-12, IFN-γ). Once activated they can directly identify and kill tumor cells [Raskov et al.,
2021]. Innate immune cells also play important roles in the tumor microenvironment. NK cells, DCs,
and M1 macrophages are all fast acting antigen presenting cells (APCs) that are heavily influenced
by and in turn contribute to the anti-tumor activity in the tumor microenvironment [Wu et al.,
2020, Shen et al., 2021].
As a tumor becomes more established, some of the tumor cells acquire changes that allow
them to evade and suppress the immune system. Some tumor cells increase expression of immunosuppressive surface ligands (e.g., PD-L1) that deactivate cytotoxic CD8 T cells. They can also
increase secretion of immunosuppressive cytokines such as transforming growth factor β (TGF-β)
and decrease expression of tumor antigens and antigen presenting machinery thus contributing to
their evasion and suppression of immune cells. Tumor cells can also recruit more immune cells to
the tumor microenvironment via secretion of chemokines such as CCL2. When these newly arrived
immune cells encounter the suppressive environment orchestrated by the tumor cells, they become
supressive or deactivated and in turn contribute to the immunosuppressive TME.
Tumors have been broadly described as immunologically ”hot” or ”cold” with sub-classifications
determined by anti-tumor immune cell infiltration or lack of infiltration into the tumor (Figure 1.2).
Hot tumors, also referred to as infiltrated-immune, are infiltrated with activated anti-tumor CD8+
T cells, have high numbers of tumor infiltrating lymphocytes (TILs) and proinflammatory cytokines
and are associated with better prognoses and responses to therapies (e.g., anti-PD-1) [Maleki Vareki,
2018]. Through a dynamic process of immunoediting, tumor cells adopt several mechanisms to evade
immunosurveillance, leading to the establishment of cold tumors that block infiltration of CD8 T
cells and reducing or preventing anti-tumor immune responses [Dunn et al., 2004, Teng et al., 2015].
Cold tumors that lack infiltration of CD8 T cells can be further classified as infiltratedexcluded tumors or immune deserts. In infiltrated-excluded tumors, T cells may be recruited to the
periphery of the tumor but are unable to infiltrate the core of the tumor due to suppressive signals
(e.g., cytokines and miRNAs) or a physical barrier as a result of ECM remodeling [Maleki Vareki,
2018, Binnewies et al., 2018]. Immune desert tumors indicate that the tumor cells do not elicit
an anti-tumor response from the adaptive immune cells [Chen and Mellman, 2017]. Both types of
non-inflamed cold tumors are typically less responsive to immunotherapy than infiltrated-immune
hot tumors [Herbst et al., 2014].
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Figure 1.2: Types of Immune Tumor Microenvironments

Another type of cold tumor, infiltrated-suppressed, is populated by myeloid-derived suppressor cells (MDSCs), M2-like TAMs, T regulatory cells (Tregs), type 2 classical dendritic cells
(cDC2), type 2 neutrophils (N2), and Th2-like Natural killer T cells (NKTIIs) [Hinshaw and Shevde,
2019, Chew et al., 2012]. For decades, most immunotherapies focused on activating CD8 T cells,
but in immunosuppressive TMEs CD8 T cell proliferation is suppressed by increased secretion of
metabolites (e.g., lactate) and immunosuppressive cytokines (e.g., IL-10) rendering T cell activation
a challenge and creating a need for immunomodulatory therapies [Tang et al., 2021]. Specifically
targeting TAMs has shown potential in shifting the type 2 immunosuppressive tumor milieu to a
type 1 immune active milieu.

1.2

Macrophages
Macrophages are phagocytic, innate immune cells classified into two extreme phenotypes,

classically activated M1 and alternatively activated M2 (Figure 1.3). M1 macrophages are stimulated by LPS and IFNγ, and are involved in Th1 pro-inflammatory responses [Mantovani et al.,
2002]. M2 macrophages are stimulated by IL-4, IL-13, and IL-10 and are involved in tissue remodeling and immunosuppressive responses [Mantovani et al., 2002]. M2 macrophages can fur-
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ther be sub-categorized into M2a, M2b, M2c, and M2d phenotypes [Shapouri-Moghaddam et al.,
2018]. However, macrophages can simultaneously express M1 and M2 related markers to exhibit
a hybrid phenotype, which confer them the ability to switch between M1 and M2 phenotypes and
to quickly respond to stimuli [Martinez and Gordon, 2014, Chávez-Galán et al., 2015]. Robust
classification of macrophages includes identification of specific cell surface markers, cytokine secretion, antigen presenting ability, preferred metabolic pathways, and transcription factor expression.
Since macrophage phenotype is so fluid a more accepted approach to classifying macrophages is to
use the terms M1-like and M2-like. Macrophages that encounter foreign debris or apoptotic cells
take on an M1-like phenotype accompanied by increased phagocytosis, antigen presentation, and
pro-inflammatory cytokine secretion that recruits and activates other immune cells to aid in the
inflammatory response [Hirayama et al., 2018, Duque and Descoteaux, 2014]. Once the foreign debris or damaged cells have been cleared, macrophages shift from a pro-inflammatory (M1-like) to
an anti-inflammatory (M2-like) state. During resolution of inflammation, macrophages release antiinflammatory cytokines, induce angiogenesis, and remodel the ECM to restore tissue homeostasis
[Mantovani et al., 2013, Corliss et al., 2016].
Macrophages often play a central role in the development and maintenance of pathologies
through misuse of their extreme functions, but research supports that altering macrophage function
results in varying degrees of relief in diseases with extreme immune profiles [Ardura et al., 2019].
Regulation of macrophage phenotype and function can be accomplished through natural microenvironment cues or through therapeutic interventions.This section will focus on the influence that
macrophages have in tumor progression and their potential as therapeutic targets.

1.2.1

Origin
Macrophages derive from either embryonic macrophages or from circulating monocytes.

In early stages of mammalian fetal development, macrophages derive from mesenchymal progenitors in the yolk sac. Shortly followed by erythro-myeloid progenitors in the liver differentiating
into macrophages. During postnatal development macrophages derive from bone-marrow derived
monocytes through hematopoiesis [Zheng et al., 2017]. In the adult mammal, macrophages are
typically categorized as tissue resident or monocyte-derived macrophages; however, tissue resident
macrophages can either derive from embryonic progenitors or monocytes, the prevalence of the latter
origin is currently under revision [Italiani and Boraschi, 2014]. The proportion of embryonic derived
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and monocyte-derived macrophages is specific to the tissue in which they reside. In some organs,
such as the brain, the majority of macrophages, known as microglia, derive from embryonic progenitors, whereas the colon macrophage population is almost entirely composed of monocyte-derived
macrophages [DeNardo and Ruffell, 2019]. The role in which macrophage origin contributes to phenotype and function in tissue-resident macrophages has not been fully explored [Franken et al., 2016].
However, transcription factors involved in macrophage differentiation are dependent on progenitor
cell origin and the tissue in which they reside suggesting variation in function depending on origin.

1.2.2

Classification

1.2.2.1

M1-like Macrophages
Macrophages play a major role in mounting an immune response against foreign microor-

ganisms and damaged cells, such as tumor cells or apoptotic cells. Interferon gamma (IFNγ) and
lipopolysaccharide (LPS) are the two stimulatory agents used to polarize macrophages to the M1
phenotype, which is associated with increased phagocytosis, antigen presentation, and proinflammatory cytokine secretion.
Phagocytosis is one of three main types of endocytosis that specializes in uptake and elimination of cell debris and foreign substances. Only a subset of cells including macrophages, neutrophils,
monocytes, dendritic cells, and osteoclasts can perform this function. Pattern recognition receptors
(PRRs) and antibody fragment crystallizable (Fc) receptors, among other receptors, allow these cells
to recognize and engulf endogenous and exogenous ligands, and macrophages, in particular, are well
known for their ability to phagocytize unwanted cells and debris [Hirayama et al., 2018]. Macrophage
phagocytosis augments anti-tumor effects of monoclonal antibody therapy, as demonstrated through
CD47 blockade in a B16 melanoma mouse model [Weiskopf and Weissman, 2015, Lecoultre et al.,
2020, Wang et al., 2013].
In addition to dendritic cells and B cells, macrophages are one of the few classical antigen
presenting cells in the immune system. Macrophages can present antigens via major histocompatibility complex II (MHCII) or MHCI. MHC II presntation allows macrophages to present antigens
from foreign microorganisms and damaged cells. Helper CD4 T cells are on the receiving end
of this transaction and in turn activate B cells leading to secretion of antigen-specific antibodies.
These antibodies bind to the microorganism or damaged cell expressing the specific antigen allow-
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Figure 1.3: M1 vs. M2 Macrophage Classification
ing macrophages to phagocytose them more readily [Duque and Descoteaux, 2014]. Although less
understood, CD169+ macrophages have been found to be involved in cross presenting antigens via
MHCI to some degree [Muntjewerff et al., 2020].
Stimulation of PRRs on macrophages initiates an immune response involving production
and secretion of pro-infammatory cytokines and chemokines, which recruit and activate more immune cells, thus inducing a specific kind of TAM reprogramming toward a pro-inflammatory state.
Interleukin-12 (IL-12) is one of the most critical pro-inflammatory cytokines released by macrophages
due to its role in activating cytotoxic CD8 T cells and NK cells [Duque and Descoteaux, 2014]. Additionally, the secretion of tumor-necrosis factor alpha (TNFα) is synergistic with other cytokines such
as IL-12 and initiates apoptotic signaling cascade [Parameswaran and Patial, 2010]. Interleukin-1β
(IL-1β) is involved in recruiting more immune cells to the site of infection, specifically hypoxic
environments, by inducing angiogenesis [Carmi et al., 2009].
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1.2.2.2

M2-like Macrophages
The potent pro-inflammatory response elicited by macrophages is balanced by their involve-

ment in inflammatory resolution and tissue repair. During resolution of inflammation, macrophages
release anti-inflammatory cytokines, induce angiogenesis, and remodel the ECM [Mantovani et al.,
2013, Corliss et al., 2016]. M2 macrophage polarization is triggered by exposure to a wide range
of stimuli and typically involves activation of transcription factors STAT3 and STAT6 [ShapouriMoghaddam et al., 2018]. However, the source of stimulation leads to differing surface markers and
biological activity, thus M2 macrophages can further be described as one of four subsets (M2a, M2b,
M2c, M2d). Although phenotypes vary among the M2 subsets, common M2 surface receptors are
CD206 and CD163 and common cytokine expression includes IL-10 [Shapouri-Moghaddam et al.,
2018].
M2a macrophages are stimulated by IL-4, IL-13 and exposure to parasites [Shapouri-Moghaddam
et al., 2018]. M2a macrophages are known as wound-healing macrophages. They are the predominant subset of macrophages involved in tissue repair. Their expression profile includes Arginase-1,
IL-10, TGF-β, MHCII and common M2 expression of CD163 and CD206 [Roszer, 2015]. This specific profile allows M2a macrophages to encapsulate, kill, and present parasites [Mantovani et al.,
2004]. Further the production of IL-10 and TGF-β can lead to the M2b and M2c phenotypes that
further help resolve inflammation.
M2b macrophages are known as regulatory macrophages and suppress immune responses
following an inflammatory response [Wang et al., 2019]. Immune complexes are the main activators
of the M2b phenotype [Shapouri-Moghaddam et al., 2018]. Interestingly, LPS can also activate the
M2b phenotype, which adds to the complexity and controversy of defining macrophages as purely M1
or M2. It also alludes to the plasticity of macrophages from pro-inflammatory to anti-inflammatory
throughout an immune response. Markers associated with the M2b phenotype include IL-1, IL-6,
IL-10, TNF-α, and CD86 [Mantovani et al., 2004].
Exposure to IL-10, TGF-β, and glucocorticoids is associated with M2c macrophages [ShapouriMoghaddam et al., 2018]. M2c macrophages are known for their increased phagocytosis of apoptotic
cells. Expression associated with the M2c phenotype include IL-10, TGF-β, and the common M2
receptors CD163 and CD206 [Mantovani et al., 2004]. M2c macrophages are commonly referred to
as deactivated macrophages because they produce immunosuppressive cytokines IL-10 and TGF-β.
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The M2d phenotype can be activated by adenosine or IL-6 exposure [Shapouri-Moghaddam
et al., 2018]. They promote angiogenesis and are often associated with tumor progression [Wang
et al., 2010]. Their markers include VEGF, IL-10, IL-12 and TGF-β [Mantovani et al., 2004]. These
M2d macrophages contribute to immunosuppression and potentially therapy resistance in various
diseases.

1.2.2.3

Metabolism
Macrophage metabolism contributes to the complexity of classifying macrophages. Most

research regarding macrophage metabolism is based on either the M1 or the M2 phenotype. However, more recent research suggests that the preferred metabolic pathways of macrophages are more
complex and require further investigation.
Generally, pro-inflammatory macrophages, often categorized as M1, utilize glycolysis, the
pentose phosphate pathway (PPP), and fatty acid synthesis as their main metabolic pathways,
whereas anti-inflammatory macrophages, M2 macrophages, tend to prefer oxidative phosphorylation
(OXPHOS) and fatty acid oxidation (FAO) [Viola et al., 2019]. Glycolysis produces very little ATP
compared to the alternative OXPHOS; however, glycolysis provides macrophages with metabolic
intermediates that are necessary for some of their pro-inflammatory functions [Diskin and PålssonMcDermott, 2018].
Some of these important intermediates for pro-inflammatory macrophages are glycolytic
enzymes, such as hexokinase and pyruvate kinase M2 (PKM2). Hexokinase can initiate PAMP
responses by functioning like a pattern recognition receptor (PRR). Additionally, hexokinase can
contribute to activation of nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome [Diskin and Pålsson-McDermott, 2018]. Activating the NLRP3 inflammasome leads to production of pro-inflammatory cytokines, such as interleukin-1α (IL-1α) and interleukin-1β (IL-1β).
Another important glycolytic enzyme, PKM2, interacts with hypoxia-inducible factor 1 α (HIF-1α)
in order to promote transcription of many pro-inflammatory genes, including IL-1β [Diskin and
Pålsson-McDermott, 2018].
Both M1 and M2 macrophages utilize the Tricarboxylic acid (TCA) cycle. Citrate that
enters the TCA cycle in M2 macrophages will complete the cycle without any deviations. However
in M1 macrophages, after citrate is converted to cis-aconitate by aconitase 2 (ACO2), some of the
cis-aconitate is converted to itaconate by decarboxylase immune-responsive gene 1 (IRG1) [Diskin
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and Pålsson-McDermott, 2018]. Itaconate, originally known for its antibacterial functions, is one of
the most prevalent intermediates in LPS-stimulated macrophages. Increased itaconate is associated
with M1 macrophages, but is a part of a negative feedback loop that returns macrophage metabolism
to an M2-like, anti-inflammatory state [Diskin and Pålsson-McDermott, 2018]. Itaconate inhibits
succinate dehydrogenase (SDH) and leads to the accumulation of succinate, which results in increased HIF-1α activation and therefore promotes more glycolysis and itaconate production. [Viola
et al., 2019]. This pathway is also upregulated in hypoxic environments, so despite itaconate being
associated with an M1 phenotype, it is found to be upregulated in tumor-associated macrophages
(TAMs) and can contribute to tumor progression [Weiss, 2020]. This along with many other findings
reminds researchers that categorizing macrophages as M1 or M2 is an oversimplification and TAMs
should be analyzed based on function, as well as phenotype.

1.3

Tumor-Associated Macrophages
Tumor-associated macrophages (TAMs) are liaisons between the innate and adaptive im-

mune response in solid tumors. TAMs are a heterogeneous population deriving from tissue resident
macrophages and circulating monocytes, the latter of which are recruited to tumors through tumor
derived CCL2 [Laviron and Boissonnas, 2019, Zhou et al., 2020]. Upon arrival, monocyte-derived
macrophages are polarized by the TME (e.g., exposure to Th2 cytokines, hypoxia, etc.) to become
TAMs. Although the origin of TAMs may play a role in their response to anti-cancer therapies, there
is little to no research in this area due to a lack of distinguishing cell markers. Regardless of origin,
TAMs exhibit various phenotypes and functions throughout tumor development and within the tumor at any given point. The conditions of the tumor microenvironment (TME) strongly influence
the functions of TAMs, however, TAM phenotype and distribution is not uniform due to pockets of
hypoxia, ECM remodeling and dynamic niches within the tumor milieu [Lewis and Murdoch, 2005].
Within these niches, TAMs can exhibit pro-tumor or anti-tumor functions, and therefore play a
significant role in tumor progression as outlined in the following sections.

1.3.1

Anti-Tumor TAMs
TAMs are a dynamic and heterogeneous population of cells. In the early stages of tumor

development, most TAMs tend to be M1-like, anti-tumor. M1-like TAMs prevent tumor growth
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through secretion of proinflammatory cytokines including IL-12, interleukin 6 (IL-6), tumor necrosis
factor (TNFα), and type I IFNs. IL-12 induces proliferation, migration, and activation of CD8+
T cells in the TME [Al-Sarireh and Eremin, 2000]. Specifically, exposure to IL-12 increases CD8+
T cell secretion of interferon gamma (IFNγ), a key indicator of CD8+ T cell cytotoxicity [Nguyen
et al., 2020]. The combination of IFNγ and TNFα are associated with even higher cytotoxicity
towards tumor cells by increasing antigen presentation on TAMs, as well as other APCs, and further
production of pro-inflammatory cytokines [Pinto et al., 2019].

1.3.2

Pro-Tumor TAMs
Once the tumor becomes more established, TAMs tend to shift to an immunosuppressive,

pro-tumor, M2-like state. Most TAMs in established tumors can be most closely associated with
the M2d phenotype [Chanmee et al., 2014, Duluc et al., 2009, Bardi et al., 2018]. This shift in
TAMs depends on the factors secreted by the tumor cells, tissue remodeling, presence of oxygen,
pH, and availability of nutrients. M2-like TAMs promote tumor growth and interfere with current
immunotherapy efficacy. They secrete MMPs, such as MMP9, that remodel the extracellular matrix
(ECM) and block activated T cells from getting to the tumor [Ceci et al., 2020]. The produce angiogenic factors that allow for neoangiogenesis, which promotes invasion and metastasis. However,
elimination of all angiogenic factors could reduce potential infiltration of T cells into the TME.
They block T cell activation with upregulated immune checkpoint ligands and they inhibit T cell
proliferation and activation by depleting essential metabolites, such as arginine [Ceci et al., 2020].
M2-like TAMs secrete anti-inflammatory cytokines, such as IL-10, that suppress dendritic cell antigen presenting function. IL-10 secreted by macrophages reduces cytotoxic CD8 T cell response by
blocking IL-12 expression by dendritic cells in mammary carcinoma [Ruffell et al., 2014]. Another
significant immunosuppressive cytokine secreted by M2-like TAMs is TGFβ [Sica, 2010]. TGFβ
is commonly found in the TME and increases Treg cell infiltration and activation [Yoshimura and
Muto, 2010]. Further, TGFβ polarizes TAMs from an anti-tumor to a pro-tumor state, creating
a positive feedback loop and augmenting immunosuppression in the TME. Not surprisingly, patients with solid tumors that have a high ratio of M2-like to M1-like TAMs have worse prognoses
[Jayasingam et al., 2020]. Thus making TAM-targeted therapies an attractive approach to reducing
tumor growth and inducing immune favorable conditions. Research supports that TAM function
can be skewed from one extreme to another and this change in function tips the balance in the TME
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from immunosuppressive to immune active [Mitchem et al., 2013, Krausgruber et al., 2011].

1.4
1.4.1

TAM-Targeted Therapy
Depleting and Preventing TAM Recruitment
Increased macrophage density is associated with tumor progression and poor clinical out-

come in most solid tumors [Ruffell and Coussens, 2015]. Early stages of TAM-targeted therapy
focused on depleting TAMs and preventing TAM recruitment. Bisphosphonates, specifically clodronate, are one of the most widely researched and clinically accepted methods for TAM depletion. Clodronate has been shown to effectively deplete TAMs and inhibit tumor growth [Zeisberger
et al., 2006, Nakao et al., 2005]. Administration of Trabectedin, a toxin derived from Ecteinascidia
turbinate, eliminates macrophages without harming other cell types, importantly lymphocytes are
left intact [Sica et al., 2008]. Not only does Trabectedin deplete macrophages, but it also inhibits
CCL2 production which specifically prevents TAM recruitment [Sica et al., 2008]. Common receptors
involved in TAM recruitment and survival are colony-stimulating factor 1 (CSF-1) and chemokine
(C-C motif) receptor 2 (CCR2). Inhibiting one or both of these receptors effectively reduces the
TAM population and improves CD8 T cell suppression [Mitchem et al., 2013]. Since a higher ratio
of M1-like TAMs to M2-like TAMs is associated with better prognoses [Macciò et al., 2020, Pinto
et al., 2019, Conway et al., 2016], reprogramming TAMs has been and continues to be an enticing
immunomodulatory therapy.

1.4.2

Reprogramming TAMs
Reprogramming TAMs takes advantage of the plasticity and pro-inflammatory influence

that TAMs could play on the TME. The notion that TAMs are associated with poor prognosis
does not consider the ratio of M1 and M2 in TAMs. One of the reasons is attributed to a lack of
consistent M1 and M2 markers leading to conflicting data of TAM infiltration being associated with
tumor progression. When M1 or M2 TAMs are further identified, it is shown that a higher ratio
of M1-like TAMs to M2-like TAMs is associated with better prognosis [Macciò et al., 2020, Pinto
et al., 2019, Conway et al., 2016]. An effective way to categorize TAMs for future studies has
been well reviewed elsewhere [Jayasingam et al., 2020]. TAM reprogramming is a dual-pronged
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therapy that not only reduces immunosuppressive M2-like TAMs, but also increases immune active
M1-like TAMs.TAM-targeting strategies include surface receptor inhibition or activation, epigenetic
regulation, and intracellular signaling alterations.
Activation of M1-associated surface receptors can be accomplished through directed delivery
of antibodies, cytokines, or attenuated pathogens. Activating CD40, a co-stimulatory ligand on
TAMs involved in antigen presentation and T helper cell activation, stimulates pro-inflammatory
cytokine secretion and anti-tumor activity in TAMs. Specifically, anti-CD40 mAb induce production
of tumoricidal nitric oxide (NO) and TNFα [Lum et al., 2006]. Another family of surface receptors
that have been successfully targeted for macrophage polarization are toll-like receptors (TLRs).
TLR agonists, such as TLR7/8, effectively skew TAMs from M2-like to M1-like [Rodell et al., 2018].
TLR4 agonists, such as LPS, are widely accepted in shifting macrophages from M2 to M1 phenotype.
In particular, paclitaxel, originally a chemotherapeutic agent, alters TAM phenotype from M2-like
to M1-like in breast and melanoma tumor models in a TLR4-dependent manner [Wanderley et al.,
2018]. Other macrophage associated receptors, such as c-type lectin receptors (CLRs), can be
activated by attenuated pathogens to induce M1 polarization. For instance, β-glucans can be used
to activate a pro-inflammatory TAM phenotype [De Graaff et al., 2021].
The complexity of macrophage polarization provides a broad range of potential intracellular
signaling targets including metabolic intermediates, enzymes, and transcription factors. These pathways can be targeted through intracellular delivery of RNAs, proteins, and other small molecules.
The M2 polarization of TAMs has been blocked with intracellular M2 related pathway inhibitors,
such as STAT3, STAT6 and PI3K [Tang et al., 2012, Genard et al., 2017]. PI3Kγ inhibition induces
a shift in TAM metabolism by suppressing Arginase 1 (Arg1) and promoting NOS2 [Kaneda et al.,
2016]. Metabolic reprogramming of TAMs has great potential and is reviewed extensively elsewhere
[Puthenveetil and Dubey, 2020]. Activating M1 transcription factors (e.g., NF-κB and STAT1)
and administering pro-inflammatory cytokines (e.g., IFN-α2, IL-2 and IL-12) have clinical success
in skewing TAMs to an M1-like phenotype [Tang et al., 2012, Genard et al., 2017, Josephs et al.,
2015, Tähtinen et al., 2015]. Preliminary research supports the potential of TAM-targeted therapies focusing on epigenetic (e.g., HDACi Trichostatin A) and metabolic (e.g., Gpr132 inhibition)
regulation [de Groot et al., 2018]. Transcriptional, epigenetic, and metabolic regulation of TAMs is
extensively reviewed in Larionova et al.[Larionova et al., 2020]. Many of these TAM reprogramming
treatments have shown success in altering the TME but often cause systemic toxicity [Berraondo
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et al., 2018, Cen et al., 2018].
To reduce off-target delivery, viral and nonviral vectors have been engineered to improve
TAM-directed delivery [Niu et al., 2014, Han et al., 2021, Zhang et al., 2018]. Regardless of the type
of vector used, the vector needs to be engineered to enhance macrophage specificity. The rest of
this chapter will focus on effective (1) TAM-targeted delivery methods via Adenovirus and Zymosan
and (2) TAM reprogramming by targeting macrophage polarizing transcription factors in the IRF
family.

1.5

TAM Reprogramming Delivery Methods
TAM plasticity allows TAMs to be skewed from pro-tumor to anti-tumor through direct de-

livery of M1 polarizing agents as discussed. A variety of vectors can be used to carry these polarizing
factors into TAMs. Vectors are nonintegrating to induce transient gene expression. Immunogenicity
and insertion size must be considered in choosing the appropriate vector. Viral vectors including
nonintegrating lentiviral vectors, adeno-associated viral vectors, and adenoviral vectors have high
macrophage-specificity with large DNA cloning capacities [Milone and O’Doherty, 2018, Poltavets
et al., 2020, Doronin et al., 2012]. Liposomes and exosomes, two nonviral vectors, have also been
used in TAM-targeted therapy [Takano et al., 2003, Barnes and Somerville, 2020]. These small
particles can be used to encapsulate and deliver cytokines and other M1-polarizing factors directly
to TAMs. However, none of these vectors are exclusively TAM-specific.
The most versatile approach for targeting TAMs is to use customizable nanoparticles.
Nanoparticles can be engineered to have the optimal chemical composition, shape, size, and charge
for macrophage uptake [Harrison et al., 2018]. However, nanoparticles can be expensive and therefore
alternative options should still be explored. Successful gene therapy requires a vector that carries the
gene of interest specifically to tumor-associated macrophages. Regardless of the chosen vector, there
are modifications that can increase TAM specificity by preventing the vector from being consumed
while in circulation and more directly guiding the vector to TAMs. The following sections will focus
on using an adenoviral vector and zymosan to increase TAM-specific gene delivery.
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1.5.1

Adenoviral Vectors for TAM Gene Delivery
Adenoviruses are non-enveloped viruses with an icosahedral nucleocapsid and linear dsDNA.

There are seven species of human adenoviruses consisting of more than 60 serotypes, of which, C5,
is the most widely used in oncolytic virus-based cancer immunotherapies and cancer therapeutic
vaccines [Dhingra et al., 2019]. In either case, these adenovirus-based therapies involve increasing
expression of pro-inflammatory cytokines and tumor-associated antigens to alter the TME and promote T cell activation [Sato-Dahlman et al., 2020]. Adenoviruses are an attractive vector for TAM
gene delivery because they can be replication deficient, carry large amounts of DNA, and have transient gene expression. However, they infect a wide range of cell types, can be highly immunogenic,
and can be eliminated before successful gene transfer.
Genetic modifications of Ad5 allow them to have selective replication or to be completely
replication deficient. Ad5 has two important coding regions, E1A and E1B, required for viral DNA
expression and replication. Oncolytic adenoviral vectors have deletions or substitutions in their E1A
regions that allows for selective replication in cancer cells [Wold and Toth, 2013]. Whereas, complete
replication deficiency is achieved in adenovirus-based therapeutic vaccines by deleting the E1A and
E1B regions from the adenovirus genome [Wold and Toth, 2013]. Not only do these deletions
prevent viral replication, they also increase the amount of foreign DNA that can be packaged into
the recombinant adenovirus. Specifically, adenoviruses can carry 8-36kb of foreign DNA [Lee et al.,
2017].
Transient gene expression is necessary when altering the inflammatory state of the tumor
microenvironment (TME). Chronic inflammation due to permanent pro-inflammatory changes in
TME would most likely result in tumor growth and poor clinical outcome. Adenoviruses do not
integrate their genes into the host cell genome, unlike lentiviruses [Burke et al., 2002]. Adenoviruses
have glycoprotein fibers on their surface, which are recognized by the coxsackie and adenovirus
receptor (CAR) and integrins, which are found on the surface of most cells (immune and non-immune
cells). Once the glycoproteins bind to CAR and integrins, the adenovirus is endocytosed. In the
cytoplasm, the integrins begin the uncoating process of the adenovirus, which exposes protein VI
allowing for endosomal penetration and escape of the adenoviral particles [Fejer et al., 2011]. Dynein
transports the adenoviral particles on microtubules to the nuclear pore complex. Where it increases
nuclear permeability and injects its viral DNA into the nucleus for transcription. Without the E1A
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and E1B coding regions, the linear dsDNA from the adenovirus is transcribed, not replicated. The
transcribed DNA insert is exported from the nucleus and translated via ribosomes, as per usual.
Adenoviral vectors can be highly immunogenic and can therefore elicit an inflammatory
immune response [Hassan et al., 2018]. Adenovirus is coated with coagulation factor X, which
directly binds to and activates Toll-like receptor 4 (TLR4) in macrophages [Doronin et al., 2012].
This additional inflammatory stimulus could be beneficial in TAM reprogramming from M2 to M1.
However, high doses of adenovirus triggers macrophage cell death, so dose-escalation studies are
crucial [Shirley et al., 2020]. Further reduction in immunogenicity can be achieved by deleting the
E3 gene from Ad5. Deleting the E3 coding region reduces MHC immune response to the recombinant
adenovirus [Wold and Toth, 2013].
Two drawbacks of using an adenoviral vector to target TAMs are potential pre-existing
immunity against the adenovirus and infecting multiple cell types. Since adenoviruses are commonly
used in vaccines and humans can be exposed to them in nature, there is a possibility that the host has
already been exposed to the adenovirus. If this is the case, then antibodies can potentially destroy
the vectors before they successfully transfer their genes to the target cells [Shirley et al., 2020].
In the same vein, adenoviruses infect any cell that expresses CAR and accompanying integrins.
Modifications can be made to the surface of adenoviral vectors to evade early immune rejection
and non-specific uptake. In this research, the adenovirus is delivered to TAMs via conjugation to
zymosan particles.

1.5.2

TAM-Targeting Particles

1.5.2.1

Overview of Particles
Characteristics of the TME, such as low pH and irregular vasculature, have been used to

design nano carriers that accumulate and release their contents specifically at tumor sites [Hu et al.,
2019]. Early delivery particles used polyethylene glycol (PEG), non-toxic polymer, coatings that are
sheddable in low pH environments [Dehaini et al., 2016, Pei and Yeo, 2016]. Thus, PEG disguises
vectors while moving through healthy tissue and is shed once it reaches the acidic TME. Another
TME sensitive polymeric [poly(β-amino ester)] nanoparticle encapsulating IL-12 effectively reprogrammed M2-like to M1-like TAMs with insignificant systemic effects [Wang et al., 2017]. Besides
polymer coatings, another TME-targeting strategy is magnetism. Magnetic particles can release
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their contents in the TME when guided by an external magnetic field [Rao et al., 2020]. However,
designing delivery systems to effectively accumulate and release their contents at tumor sites has
been an obstacle. Due to the enhanced permeation and retention (EPR) effect, many nanoparticles
effectively accumulate at tumor sites but do not release their contents efficiently. The development
of a more efficient delivery system relies on a liposome engineered with a sphingomyelin lipid coating and ferric particles [Medina et al., 2020]. Together these enzymatic and magnetic functions
synergistically increase accumulation and release of contents in the tumor microenvironment.
The ability of macrophages to recognize and phagocytize damaged cells and foreign material
is accompanied by a few families of specific pattern recognition receptors (PRRs) including scavenger
receptors (SRs) and c-type lectin receptors (CLRs). Unlike tumor cells, macrophages are genetically
stable and therefore have more predictable receptor expression depending on the state of the TME.
M2-like TAMs have significant expression of these PRRs making them prime candidates for TAM
directed delivery (Table 1.1).
Scavenger receptors, originally defined as oxidized LDL receptors, are now known to be a
heterogeneous family of PRRs capable of binding to a broad range of damage-associated molecular
patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)[Canton et al., 2013]. SRs
contribute to the inflammatory and metabolic states of macrophages and are therefore prime candidates for uptake of TAM-targeting particles. Dual targeting M2-like nanoparticle (M2NP) coated
with α-peptide, mimicking apolipoprotein A1 (ApoA1), binds with high affinity to scavenger receptor B type 1 (SR-B1) on TAMs [Qian et al., 2017]. Another SR found on TAMs is the “macrophage
receptor with collagenous structure” (MARCO). MARCO was found to be uniquely expressed in
TAMs in the TME of B16 melanoma making it an excellent candidate for TAM-targeted delivery
[Georgoudaki et al., 2016]. Yet another SR, CD163, a hemoglobin scavenger receptor is upregulated on M2 macrophages and has been effectively used to direct liposomes to M2-like macrophages
[Etzerodt et al., 2012].
CLRs are a family of receptors involved in antigen uptake in antigen presenting cells. They
recognize and bind to glycan-associated structures found on other cells or pathogens. One of the
most widely targeted CLR for TAM directed delivery is CD206, a mannose receptor. Not only
is CD206 found on TAMs, but more importantly it is upregulated on immunosuppressive M2-like
TAMs. Mannosylated nanocarriers are directly taken up by TAMs at high efficiency and specificity
[Shi et al., 2018, Zhang et al., 2019, Ortega et al., 2014]. Glycocalyx-mimicking nanoparticles
21

TAM
Receptor

CD206

Vehicle

GOI/
Modulator

Study

Findings

Dimannose/PGA

IRF5/IKKβ
mRNA

Clinical [Zhang
et al., 2019]

M2 to M1;
promotes tumor
regression

Photosensitizers

In vivo [Shi
et al., 2018]

M2 to M1;
enhances
recruitment of
CTL in TME

miR-155

In vivo [Liu
et al., 2017]

M2 to M1;
activates T
lymphocytes and
NK cells in TME

Man/PEGPLGA

sPEG/GLC

Dectin-1

PLGA

R848, MIP3α

In vivo [Da Silva
et al., 2019]

M2 to M1;
inflammatory
phenotype in
tumor-draining
lymph node

Man-siRNA
complex

Potential:
NF-κB or
JAK-STAT
pathway

In vivo [Ortega
et al., 2014]

enhances
TAM-targeting

Glycocalyx

Glycocalyx

In vivo [Zhang
et al., 2018]

M2 to M1;
enhances
anti-PD-L1 efficacy

SR-B1

α-peptideM2pep/PEG

CSF-1R siRNA

In vivo [Qian
et al., 2017]

M2 targeting and
depletion from
TME; decreases
tumor size and
prolongs survival

MARCO

Anti-Marco ab

MARCO

In vivo
[Georgoudaki
et al., 2016]

M2 to M1;
enhances
checkpoint therapy

CD163

AntiCD163/PEG
liposomes

Calcein

In vivo
[Etzerodt et al.,
2012]

CD163
monocyte-derived
macrophage
specificity

IRF3

Pre-clinical
[Zhuang et al.,
2020]

M2 to M1;
increases
proliferation and
cytotoxic function
of CD8 T cells

TLR4

Sophoridine

Table 1.1: Pre-Clinical TAM-Targeted Immunomodulatory Therapies
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preferentially bind to M2-like TAMs via mannose receptor and macrophage galactose lectins inducing
M1 polarization and improving response to anti-PD-L1 immunotherapy [Zhang et al., 2018, Su et al.,
2015]. Another common TAM-targeting agent is zymosan, a PAMP recognized by innate phagocytic
immune cells. Zymosan is a promising delivery particle for TAM-targeted therapy.

1.5.2.2

TAM-Targeting via Zymosan
Zymosan is a glucan component of the cell wall of Saccharomyces cerevisiae. Specifically,

it is an insoluble β-1,3-glucan structure widely used as an immunomodulatory agent. Zymosan is a
prime candidate for delivering recombinant adenoviruses to TAMs because it limits tropism of the
adenovirus and is a known anti-cancer agent. Of note, zymosan can be taken up by neutrophils,
dendritic cells, and B cells; however, the focus of this study is on macrophage uptake of the zymosanadenovirus particles but future studies should explore uptake by other immune cells.
As previously discussed, adenoviral vectors are non-specific and therefore infect any type of
cell. In order to decrease the tropism of the adenovirus, researchers have coated the vector in ligands
specific to the target cell or tissue (e.g., PEG coating for tumor directed delivery). As a phagocytic
cell, macrophages express several receptors that are only expressed on few other cell types including
neutrophils and dendritic cells. The most promising targets for macrophage directed delivery are
their PRRs. Zymosan is specifically recognized and phagocytosed by innate phagocytic cells. Uptake
occurs through PRRs Dectin-1 and TLR2 [Brown et al., 2002, De Graaff et al., 2021]. Dectin-1 is a
c-type lectin receptor (CLR) that recognizes both β-1,3 and β-1,6 glucan structures [Taylor et al.,
2002]. TLR2 is a toll-like receptor that forms heterodimers with TLR1 and TLR6 on the surface
of innate immune cells. Since these receptors are upregulated on innate phagocytic cells, particles
coated in or conjugated to zymosan targets these cells with high efficiency. Although zymosan can
be engulfed by dendritic cells and neutrophils, a zymosan coating can improve macrophage-specific
uptake of particles. In a 4T1 breast tumor mouse model, β-glucan coated nanoparticles delivered
siRNA specifically to TAMs with minimal off-target uptake [Zhang et al., 2015]. An extensive
review of β-glucan based delivery systems supports enhanced uptake of particles coated in zymosan
by phagocytic cells [Su et al., 2021].
Zymosan is a known anti-cancer agent. As a PAMP, zymosan induces a pro-inflammatory
immune response following Dectin-1 or TLR2 activation. Yeast derived β-glucan effectively shifts
macrophages from M2 to M1 and reduces tumor growth in melanoma and lung cancer [Liu et al.,
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2015].M1 polarization is induced in a Syk-dependent manner following Dectin-1 activation [Liu
et al., 2015]. In NSCLC, two weeks of β-glucan treatment reduced immunosuppression in the TME
[Albeituni et al., 2016]. Zymosan increases production of TNFα and inhibits the immunosuppressive
activity of IL-10 [Du et al., 2006]. Therefore by coating the vector in zymosan, the vector itself
becomes an accessory in M2 to M1 TAM reprogramming.

1.6

TAM Reprogramming Genes of Interest: Interferon Regulatory Factors
A network of intrinsic signaling pathways regulates macrophage polarization. Specifically,

the production of type I IFNs has been shown to enhance the anti-tumor function in TAMs. Type
I IFNs have been found to play a role in preventing oncogenesis and metastasis whilst increasing
inflammation, tumor infiltrating lymphocytes, and tumor cell cytotoxicity [Zitvogel et al., 2015].
Further type I IFNs upregulate surface expression of MHC I and MHC II, thus improving antigen
presentation of tumor-associated antigens [Musella et al., 2021]. Tumor targeted type I IFNs are
approved for clinical use in several types of cancer through delivery of fusion proteins, activation
of PRRs, and adoptive cell transfer [Zitvogel et al., 2015]. Altering IRF expression and activation
in macrophages promotes type I IFN production. Thus, IRFs are a promising target to not only
attenuate pro-tumor TAM functions but also to convert them into anti-tumor TAMs, leading to
a dual-pronged effect in reversing the immunosuppressive TME compared to direct TAM deletion
approaches.
There are nine known IRFs (IRF1-9) in mammals that can further be subcategorized according to biological purpose [Günthner and Anders, 2013]. IRFs have conserved specific DNA-binding
domains that allow them to bind to interferon-stimulated response elements (ISRE) in the promoters
of various IFN-related genes. Silencing or enhancing certain IRFs can restore antitumor functions
to TAMs and potentially improve immune activity in the TME and systemic immunity. Of the
IRFs, there are four that have the greatest potential in TAM reprogramming from a pro-tumor to
anti-tumor state including IRF3, IRF4, IRF5, and IRF7. Due to resource availability, all of these
potential transcription factors could not be explored; however, each of them could be investigated
using the same zymosan-adenovirus delivery particle.
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1.6.1

IRF4 and IRF5
IRF4 is one of the most influential transcription factors involved in M2 polarization and is

considered a reliable marker of the M2 phenotype [Wang et al., 2014]. Exposure to IL-4, association
with MyD88, and histone demethylation by JMJD3 are required for IRF4 activation [Platanitis and
Decker, 2018]. IRF4 binds to ISRE and promotes M2 associated gene expression while preventing
pro-inflammatory expression through MyD88-dependent NF-κB activation [Chistiakov et al., 2018].
IRF4 ablation in DCs enhances Th1 response and reduces Th2 response in colorectal cancer [Zhang
et al., 2020], suggesting that TAM specific inhibition of IRF4 should be explored.
IRF4 competes with IRF5 for the same binding site on MyD88. Stimulation of TLRs,
association with MyD88, and ubiquitination allow IRF5 to translocate to the nucleus and bind to
ISRE [Balkhi et al., 2008]. IRF5 plays a key role in M1 polarization by inducing the transcription
of IL-6, TNFα, and IL-12, among other proinflammatory cytokines and suppresses expression of
anti-inflammatory cytokines, such as IL-10 [Günthner and Anders, 2013]. A synthetic activated
form of IRF5 has been engineered by replacing serine residues with aspartate [Chen et al., 2008].
TAM-targeted nanoparticle delivery of activated IRF5 in ovarian tumors skews TAMs to an M1-like
state and increases CD8+ T cell infiltration [Zhang et al., 2019]. IRF5 is known to play a role in
the development of autoimmune disorders, so overexpression of IRF5 in macrophage gene therapy
must be transient [Günthner and Anders, 2013]. A promising approach to reprogramming TAMs is
to concurrently block IRF4 activation and promote IRF5 activation.

1.6.2

IRF3
IRF3 is the only IRF that constitutively resides in an inactive form in the cytoplasm of

macrophages. Upon PRR stimulation, one of two kinases, TANK-binding kinase 1 (TBK1) or
inhibitor of NF-κB kinase ϵ (IKKϵ) phosphorylate IRF3 at serine residues in the C-terminal domain
[Fitzgerald et al., 2003]. Phosphorylated IRF3 forms homodimers or heterodimers with other IRFs
and translocates into the nucleus where it interacts with CBP/p300, β-catenin, and other co-factors
to activate transcription of type I IFNs and other proinflammatory genes (Figure 1.4) [Hiscott,
2007, Petro, 2020]. Alternatively, phosphorylated IRF3 can form a heterodimer with Bax leading to
mitochondrial release of cytochrome C and apoptosis [Petro, 2020].
IRF3 is a promising candidate for TAM reprogramming because it promotes a pro-inflammatory
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Figure 1.4: IRF3 and IRF7 Activation
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phenotype that can influence the tumor milieu. IRF3 is one of the main transcription factors activated by TLR agonists, which are currently approved in clinical trials as adjuvant therapy for immune checkpoint inhibitor therapy [Pathria et al., 2019]. IRF3 promotes transcription of CXCL10,
RANTES (CCL5), IL-12p35, IL-15, arginase-2 (Arg2), and type I IFNs [Yanai et al., 2018]. CXCL10
plays an important role in T cell activation and infiltration in the TME and has been shown to be
critical to induce an anti-tumor response following immune checkpoint therapy [House et al., 2020].
CCL5 attracts effector and memory T cells to the site of the tumor but has also been associated with
tumor metastasis [Li et al., 2021a]. As previously mentioned, IL-12 induces T cell activation. IL-15
plays a role in regulation of memory CD8 T cells as well as development of NK T cells [Watkins
et al., 2009]. Arg2 is a metabolic enzyme involved in arginine metabolism and down-regulation of
nitric oxide synthesis [Viola et al., 2019]. Interestingly, Arg2 is a downstream mediator of IL-10 and
could be more closely associated with immunosuppression rather than immune activation [Dowling
et al., 2021]. Type I IFNs have been found to play a role in preventing oncogenesis and metastasis,
whilst increasing antigen presentation, inflammation, tumor infiltrating lymphocytes and tumor cell
cytotoxicity [Zitvogel et al., 2015].
Global knockout models of IRF3 have shown conflicting effects in tumor progression and
immune activation. IRF3 knockout mice had more colonic tumors and higher tumor burden than
their wild type counterparts [Tian et al., 2020]. However, IRF3 knockout in a B16F10 melanoma
tumor model showed reduced tumor size suggesting that IRF3 plays a role in tumor promotion
[Yanai et al., 2018]. In a pancreatic cancer tumor model IRF3 activation was associated with upregulation of M2-associated expression including TGF-β, CD163, CD204, and IL-10 [Fan et al., 2022].
The conflicting data suggests that there is much to be explored about the role that IRF3 plays in
macrophage function in the tumor microenvironment. Synthetic activated forms of IRF3 have been
engineered by replacing residues at several positions in the C-terminal binding domain with phosphomimetic aspartate [Romieu-Mourez et al., 2006]. Research suggests that the constitutively active
form of IRF3 in macrophages in the context of both viral infections and cancer has similar effects
through increased expression of type I interferons, as well as cytokines that regulate angiogenesis,
invasion, and apoptosis. Macrophages transduced with activated IRF3 had increased expression
of IL-12, decreased expression of VEGF and MMP-2, and enhanced tumoricidal functions against
multiple human cancer cell lines [Romieu-Mourez et al., 2006].
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1.6.3

IRF7
Unlike IRF3, IRF7 is not constitutively present in the cytoplasm of most cells with the

exception of pDCs. The early immune response following PRR activation involves IRF3 mediated
transcription of IFN-related genes including TNF-α, which induces IRF7 expression [Wang et al.,
2008]. Once IRF7 is formed it is in latent form consisting of a DNA binding domain and an
activation domain, which includes an IRF association domain and a linker domain [Antonczyk
et al., 2019]. Activation of endosomal TLR7/8/9 leads to MyD88-dependent activation of IRF7
via phosphorylation by TBK1/IKKϵ [Chiang and Liu, 2019]. Phosphorylation occurs in two sets of
serine residues in the C-terminal activation domain [Caillaud et al., 2005]. Activated IRF7 can form
homodimers or heterodimers with IRF3 or IRF5 [Andrilenas et al., 2018].
Dimerized IRF7 translocates to the nucleus where it promotes transcription of type I IFNs
and other proinflammatory cytokines (Figure 1.4) [Chiang and Liu, 2019]. Specifically, IRF7 induces expression of IFNα, IFNβ, CXCL10, CCL5, and IL-15 [Goubau et al., 2009, Sweeney, 2011].
Although there is significant overlap between IRF3 and IRF7 target genes, they do have distinct
functions. IRF3 promotes apoptosis more significantly than IRF7 [Romieu-Mourez et al., 2006].
Interestingly, IRF7 increases IL-6 mRNA stabilization but does not directly effect IL-6 promoter
activity [Sweeney, 2011]. IL-6 has been associated with pro-tumor and anti-tumor functions [Fisher
et al., 2014]. In human monocyte derived macrophages, IRF7 blocks immunosuppressive IL-10 production [Pinilla-Vera et al., 2016]. IRF7 has also been shown to play an important role in monocyte
differentiation to macrophages [Lu and Pitha, 2001]. In several studies, IRF7 has demonstrated antitumor functions. For instance, silencing IRF7 in breast cancer led to immune escape and increased
metastasis [Bidwell et al., 2012]. IRF7 was shown to contribute to M1 characteristics in TAMs in a
leukemia mouse model leading to prolonged survival [Yang et al., 2018].
Constitutively active IRF7 can be produced by substituting Ser-477/479 with phosphomimetic aspartate in the C-terminal [Hiscott, 2007]. IRF7 can also be synthetically activated by
deleting amino acids 247-467, removing the nuclear export and inhibitory domains [Romieu-Mourez
et al., 2006]. Overexpression of IRF7 in macrophages improved tumor-specific cytotoxicity and
production of pro-inflammatory cytokines, such as IL-12, by macrophages [Hiscott, 2007, RomieuMourez et al., 2006]. Macrophages transduced with recombinant adenovirus encoding active IRF7
(Ad-7) showed increased expression of MHC co-stimulatory molecules, CD40, CD80, and CD86
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[Goubau et al., 2009]. Further, simultaneous administration of B16 tumor cells and Ad-7 transduced macrophages reduced tumor growth in C57BL/6 mice suggesting that IRF7 transcription
induces anti-tumor functions in TAMs [Goubau et al., 2009].

1.7

Summary
This summary highlights two key studies that formed the basis of this research. Recom-

binant adenoviruses encoding constant active IRF3 and IRF7 promote anti-tumor activity via coculture with tumor cells and transduced macrophages [Romieu-Mourez et al., 2006]. However, their
research did not include an in vivo study. Romieu-Mourez et al. shows the potential of recombinant adenoviruses encoding IRF3 and IRF7, but they do not address in vivo macrophage delivery.
Since adenoviruses have a broad tropism, direct transduction of macrophages with recombinant
adenoviruses is only practical for adoptive cell transfer. To explore the possibility of recombinant
adenoviruses encoding constant active IRF3 and IRF7 inducing TAM reprogramming in vivo this
research proposes the need to conjugate the adenovirus to a delivery particle that will reduce the
tropism of the adenovirus and increase its uptake by macrophages.
Targeting PRRs is a common way to direct particles toward phagocytic cells, including
macrophages, dendritic cells, and neutrophils. Many PRR ligands have been explored and have
shown potential in TAM reprogramming; however, zymosan stands out as a safe, biodegradable,
known anti-cancer agent. In particular one study investigates the shift from M2-like to M1-like
macrophages induced by yeast-derived β-glucan, including zymosan [Liu et al., 2015]. Liu et al.
specifically investigates metabolic reprogramming, changes in gene expression, uptake mechanism,
and flow cytometric analysis of macrophage phenotype and CD4/CD8 T cell populations from an
in vivo mouse tumor model. However, similar to Romieu-Mourez et al., Liu et al. utilizes adoptive
cell transfer, in which they pre-treat macrophages with β-glucan. They specifically investigate
the uptake mechanism of β-glucan via Dectin-1, which supports its targeting of phagocytic cells.
They find that mice injected with pre-treated TAMs leads to a reduction in tumor burden and
neoangiogenesis supporting its potential in TAM reprogramming and inducing in vivo therapeutic
effects. The research done by Liu et al. supports the use of zymosan as both a delivery particle and
as a TAM reprogramming agent.
The particular focus of this research was to investigate the potential to induce an M1-
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like phenotype with a non-traditional approach via novel conjugated zymosan-adenovirus particles
encoding constant active IRF3 or IRF7. When delivered alone, adenoviruses have a broad tropism
and therefore do not directly target macrophages, so to limit tropism, adenoviruses were conjugated
to zymosan particles. Zymosan is a PAMP, deriving from the cell wall of yeast, including β-1,3glucan that is recognized and phagocytized by C-type lectin receptor, Dectin-1, and toll-like receptor,
TLR2, found on phagocytic cells [Brown et al., 2002, De Graaff et al., 2021]. As a PAMP, zymosan
itself induces a pro-inflammatory response and has been used as an anti-cancer agent in several solid
tumors [Liu et al., 2015, Albeituni et al., 2016, Du et al., 2006]. IRF3 and IRF7 are not classic M1
transcription factors, rather they promote transcription of type I IFNs and other pro-inflammatory
cytokines. As type I IFNs are associated with anti-tumor function in the TME and a higher M1:M2
ratio is associated with good prognosis, this work explored the potential of promoting a shift from
an M2-like to an M1-like phenotype by delivering zymosan-adenovirus conjugates encoding constant
active forms of IRF3 and IRF7. The zymosan-adenovirus particle itself is a combination of two
PAMPs and therefore should induce a pro-inflammatory response. The potential of the addition of
constant active IRF3 and IRF7, and their activation of non-traditional M1 cytokines, to enhance
this shift and/or contribute to enhanced therapeutic effects was also investigated.
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1.8

Specific Aims
An immunosuppressive tumor microenvironment (TME) leads to cancer growth, metastasis,

and therapeutic resistance. Immunomodulatory immunotherapy aims to shift the immunosuppressive TME back to an immune active state. Tumor-associated macrophages (TAMs) are a critical
component of the TME that are actively involved in tumor-specific inflammation and immunosuppression. TAMs exhibit a diverse range of phenotypes and functions, from pro-tumor to anti-tumor.
The plasticity of TAMs makes them a promising target for immunotherapy, and TAM-targeted therapies via different strategies have shown great potential. This research investigates the potential
of zymosan-adenovirus conjugate particles to induce phenotypic changes in TAMs and potential as
an intratumoral immunomodulatory therapy. The potential of recombinant adenoviruses encoding
constant active interferon regulatory factors, IRF3 and IRF7, to promote a pro-inflammatory, antitumor associated response and enhance therapeutic effect is explored.

Aim 1. Investigate Zymosan:Adenovirus as a TAM reprogramming treatment in
vitro.

Aim 1a. Evaluate macrophage uptake of Zymosan:Adenovirus conjugates using Zym:Ad
GFP with fluorescence microscopy and flow cytometry.

Aim 1b. Determine phenotypic changes induced by Zymosan:Adenovirus through analysis of M1 and M2 relative gene expression, cytokine expression, and transcription factor
expression.

Aim 2. Determine efficacy of intratumoral injection of Zymosan:Adenovirus in a
B16 double tumor mouse model.

Aim 2a. Investigate changes in immune status of the tumor microenvironment induced
by Zymosan:Adenovirus.
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Aim 2b. Investigate induction of systemic immunity by Zymosan: Adenovirus.

Aim 2c. Assess therapeutic benefit of Zymosan:Adenovirus compared to Zymosan:Adenovirus
encoding constant active IRF3 or IRF7 as determined by tumor growth curve analyses.
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Chapter 2

Altering Tumor-Associated
Macrophage Phenotype with
Zymosan-Adenovirus in vitro
2.1

Abstract
M2-like tumor associated macrophages (TAMs) play a significant role in immunosuppressive

conditions in the tumor microenvironment (TME). On the contrary, M1-like TAMs have been associated with better prognosis and immune active TMEs. Thus TAM reprogramming, a dual-pronged
therapy, that reduces immunosuppression and induces immune favorable conditions in the TME has
been a topic of investigation in solid tumors. TAM reprogramming involves two key components
including method of delivery and the contents of the delivery (e.g., gene therapy, siRNA, cytokines).
In this study, recombinant adenoviruses encoding active forms of interferon regulatory factor 3
(IRF3) and interferon regulatory factor 7 (IRF7) were conjugated to zymosan particles to target
phagocytic cells to create a pro-inflammatory, anti-tumor phenotype in TAMs. Macrophage uptake of the zymosan-adenovirus particles was determined through fluorescence microscopy and flow
cytometric analysis. TAM phenotypic reprogramming was indicated by upregulation and downregulation of M1 and M2 associated genes, respectively, as well as cytokine and transcription factor
expression in vitro. Results indicate that the zymosan-adenovirus delivery particle itself was po33

tent enough to alter the TAM phenotype, regardless of encoding constant active forms of IRF3 and
IRF7. Future work should assess changes in TAM function and metabolic state following treatment with the zymosan-adenovirus conjugate particles. This study prompts investigation of this
zymosan-adenovirus conjugate as an immunomodulatory treatment in vivo.

2.2

Introduction
The immune status of the tumor microenvironment (TME), broadly classified as “hot”

or “cold” as determined by the presence or absence of cytotoxic CD8+ T cells, respectively, is
a determining factor for tumor progression and immunotherapy efficacy [van der Woude et al.,
2017, Binnewies et al., 2018]. Immunologically cold tumors lack tumor antigens, active antigen
presenting cells, and effective T cell stimulation, thus hindering current immunotherapies including
therapeutic vaccines, immune checkpoint inhibitors, and adoptive cell transfer [Bonaventura et al.,
2019, Tähtinen et al., 2015]. Most of these therapies are only effective in a subset of patients with
hot tumors, suggesting that converting cold tumors to hot tumors could increase efficacy in more
patients [Duan et al., 2020, Tang et al., 2016]. This conversion is determined by a shift from a Th2
immune response to a Th1 immune response (i.e., changes in immune cell and cytokine composition
in the TME). Specifically, type I interferon (IFN) production from antigen presenting cells (APCs)
has been implicated in complete dendritic cell (DC) activation, CD8+ T cell priming and overall
shift to an immune active TME [Gajewski et al., 2017]. Thus, one potential strategy to reverse the
immunosuppression in the TME is to induce a pro-inflammatory state in APCs. In this study, the
focus is on tumor associated macrophage (TAM) reprogramming.
TAMs are found in most solid tumors and play an important role in immunosuppression and
immune activation due to their wide range of functions and phenotypes in addition to their plasticity.
Most TAMs in established tumors have an M2-like phenotype, which aid in tumor progression
and resistance to immunotherapy via secretion of anti-inflammatory cytokines, matrix remodeling,
expression of suppressive ligands and depletion of arginine [Chanmee et al., 2014, Bardi et al.,
2018, Ceci et al., 2020]. Thus, M2-like TAMs are associated with poor prognosis in most solid tumors
[wen Zhang et al., 2012]. In contrast, M1-like TAMs are pro-inflammatory, cytotoxic, and a higher
M1:M2 ratio has been associated with better overall outcomes and favorable immune conditions
in solid cancers such as ovarian, breast, lung, and melanoma [Macciò et al., 2020, Pinto et al.,

34

2019, Petrillo et al., 2015, Conway et al., 2016, Oshi et al., 2020]. Therefore, reprogramming M2like TAMs to M1-like TAMs has the potential to inhibit tumor progression and enhance current
immunotherapies [De Palma and Lewis, 2013, Mitchem et al., 2013, Krausgruber et al., 2011].
TAM reprogramming involves two key components including method of delivery and modulation induced. Common methods of delivery involve modified adenoviral vectors or nanoparticles
that can be recognized by pathogen recognition receptors (PRRs), which are mostly found on phagocytic cells including macrophages, dendritic cells, and neutrophils and are stimulated by pathogen
associated molecular patterns (PAMPs) and danger associated molecular patterns (DAMPs) [Musick
and Yu, 2022, Gordon et al., 2014]. Accordingly, PRRs are commonly used for TAM targeting and
altering the immune profile of the TME [Marabelle et al., 2017]. In this study, the potential of the
delivery particle itself, zymosan conjugated with adenovirus, to induce the desired TAM modulation
was elucidated. The effects of the conjugate particle were compared to other zymosan:adenovirus
conjugate particles encoding constant active forms of either interferon regulatory factor 3 (IRF3) or
interferon regulatory factor 7 (IRF7) for possible enhancements to the phenotypic shift in TAMs.
Since the ideal anti-tumor TAM has not been completely defined, approaches to altering the phenotype of TAMs vary broadly. Transcriptional, epigenetic, and metabolic modulations have all shown
some degree of success [Larionova et al., 2020]. However, the presence of type I IFNs in the TME
has been associated with overcoming therapy resistance making interferon regulatory factors (IRFs)
prime candidates for TAM reprogramming [Cao et al., 2021].
TLR stimulation is associated with an anti-tumor response via upregulation of a proinflammatory, type I IFN response. Several TLR agonists are currently approved as adjuvant therapies for several solid tumors, and the anti-tumor effect of these TLR agonists can be attributed,
at least in part, to the activation of IRF3 and/or IRF7 and subsequent pro-inflammatory response
in macrophages [Keshavarz et al., 2021]. Since TLRs are ubiquitous, TLR agonists are not directed
toward phagocytic immune cells, resulting in a less potent pro-inflammatory shift in the TME making intracellular targets of the TLR pathway an intriguing alternative. IRF3 and IRF7 are two
transcription factors activated by TLR stimulation, and macrophages transduced with the phosphomimetic, activated forms of IRF3 or IRF7 have been shown to enhance tumoricidal functions and
induce a Th1 immune response [Romieu-Mourez et al., 2006, Goubau et al., 2009]. This research
investigates the notion that increasing IRF3 or IRF7 activity in TAMs could induce anti-tumor
phenotypic changes.
35

In the present study, zymosan conjugated with recombinant adenoviruses encoding active
forms of IRF3 or IRF7 were investigated for TAM reprogramming. When delivered alone, adenoviruses have a broad tropism and therefore do not directly target macrophages, so to limit tropism,
adenoviruses were conjugated to zymosan particles. Zymosan is a PAMP, deriving from the cell
wall of yeast, including β-1,3- glucan that is recognized and phagocytized by C-type lectin receptor,
Dectin-1, and toll-like receptor, TLR2, found on phagocytic cells [Brown et al., 2002, De Graaff
et al., 2021]. As a PAMP, zymosan induces a pro-inflammatory response and has been used as
an anti-cancer agent in several solid tumors [Liu et al., 2015, Albeituni et al., 2016, Du et al.,
2006]. The combination of zymosan and adenovirus, with or without IRF3 or IRF7, reprogrammed
TAMs in vitro as indicated by relative gene expression, cytokine expression, and transcription factor
expression, prompting future investigations into Zym:Ad therapeutic potential in vivo.

2.3
2.3.1

Materials and Methods
Recombinant adenovirus construction, production, amplification,
purification, and quantification.
Construction: Expression cassettes in pENTR4 vector flanked by recombination sites

attL1 and attL2 were shuttled to adenoviral vector pAD/PL-DEST (Invitrogen) through LR recombination according to the product manual. Recombinant adenoviruses were transformed into TOP10
competent cells and plated on LB agar medium with Ampicillin and incubated at 37°C. Colonies
were transferred to chloramphenicol LB plates and colonies with no growth were extracted using
Miniprep kit (Qiagen).
Production: Adenoviral particles linearized by digestion with PacI and 2µg of adenoviral
vector DNA was transfected into AD293 cell line (Clonetech) using LipofectamineTM 2000 (Invitrogen). Crude viral lysate was collected by centrifugation (300g for 5 min), three freeze-thaw cycles of
resuspended cell pellet, centrifugation (3,000rpm for 15 min), and stored at -80°C. Transgenes were
verified by western blot.
Amplification: Recombinant adenoviruses were amplified in AD293 cells with crude viral
lysate. Cells were harvested and centrifuged (1000rpm for 5 min). All but 5mL supernatant was
removed and stored at -80°C. Cell pellet was resuspended and subjected to three freeze/thaw cycles,
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centrifuged (1000rpm for 5 min) and stored as crude viral lysate at -80°C until purification.
Purification: Crude viral lysate was purified using the Add-N-Pure Adenovirus Purification Kit according to the manufacturer’s protocol (abm). Purification was also checked with
OD260/280 (NanoDrop One). Purified adenovirus has a ratio 1.3. After purification, viruses were
buffer exchanged with PBS using Zeba™ Spin Desalting Columns, 40K MWCO, 10 mL (Catalog
number: 87772). Virus in PBS were further concentrated with Pierce™ Protein Concentrator PES,
100K MWCO, 5-20 mL (Catalog number: 88533).
Quantification: Purified virus was quantified using Adeno-X qPCR Titration Kit (Takara
Bio). Physical titer was also calculated using the following equation: viral particle concentration =
OD260 x dilution factor x 1.1x1012 particles [Maizel et al., 1968].

2.3.2

Recombinant adenovirus IRF3 expression in vitro.
AD293 cells or Raw cells plated in 6 well plates were cultured to 80% confluency. GFP and

IRF3 recombinant adenoviruses were added into the culture at a MOI of 250. Forty-eight hours later,
the expression of GFP was confirmed under a fluorescent microscope. For IRF3, cells were collected
and total protein was extracted with RIPA Lysis and Extraction Buffer (fisher). 1 ug protein was
run on a 10% SDS-PAGE buffer and transferred onto PVDF membranes. The membranes were
incubated overnight at room temperature with a goat polyclonal anti-IRF-3 Antibody (ab245341)
(Abcam) followed by incubation with HRP conjugated goat anti-mouse antibody for one hour. As
the positive control NIH3T3 total cell lysate was used (Santa Cruz). The membranes were developed
with WesternSure® PREMIUM Chemiluminescent Substrate and the images were recorded with a
C-digit Blot Scanner (Li-Cor).

2.3.3

Zymosan adenovirus conjugation.
Zymosan particles were oxidized (sodium periodate) to form functional aldehyde groups.

Aldehyde functionalized particles were treated with ADH to form hydrazide activated terminals. Hydrazide activated terminals allowed for addition of a cross-linker (LC-SPDP) to create pyridyldithiolactivated particles. Using disulfide reducing agent (DTT), pyridylithiol-activated particles were re-
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duced to sulfhydryl-activated particles. Sulfhydryl-activated particles were then reacted with streptavidin thus conjugating streptavidin to zymosan via a disulfide linkage (1 mol streptavidin/mg
zymosan). Zymosan-streptavidin was then fully saturated with biotinylated anti-adenovirus antibodies (Bio-Rad) (4 mol biotin/1 mol streptavidin). Zymosan-streptavidin-biotin complexes were
then rotated for 2 hours with adenovirus and used immediately.

2.3.4

Cell culture.
Murine RAW 264.7 cells and B16 melanoma cells (ATCC) were cultured in high glucose

DMEM supplemented with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin at 37°C
with 5% CO2 .

2.3.5

GFP Expression Analysis.
Fluorescence Microscopy: To determine percent uptake of Zym:Ad GFP, RAW264.7 cells

were plated into 6 well plates at a density of 0.9x106 cells/well and left overnight. For zymosanadenovirus GFP treatment, conjugates at a ratio of 5:1 conjugates/cell (50 viral particles/zymosan
particle) were added into the wells and mixed well. After 48 hours, GFP uptake was imaged and
quantified using Image J software (NIH).
Flow Cytometry: To compare percent uptake of Zym:Ad GFP between RAW264.7 cells and
B16 cells, cells were plated separately into 6 well plates at a density of 0.9x106 cells/well and left
overnight. For zymosan-adenovirus GFP treatment, conjugates at a ratio of 1:1 conjugate/cell (50
viral particles/zymosan particle) were added into the wells and mixed well. After 48 hours, GFP
positive cells were analyzed with a Guava Easycyte system (Millipore).

2.3.6

Bone marrow derived macrophage (BMDM) culture.
Bone marrow cells were isolated from 3-month-old C57BL/6 mice which were induced to

macrophages in vitro according to published protocols (Duits et al. 2020). Briefly, mouse femur and
tibia were collected under sterile condition. The bones were cut open at both ends and flushed with
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PBS using a 27 ½ G needle. Bone marrow cells were filtered through a 40 µm filter and cultured in
RPMI 1640 medium supplemented with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin,
and 20ng/mL murine M-CSF (Peprotech) at 37°C with 5% CO2 . Bone marrow cells were cultured
for 7 days with fresh medium added at day three.

2.3.7

BMDM Purity.
Mouse bone marrow derived macrophages were collected from culture and resuspended in

Cell Staining Buffer (biolegend) at 5-10 x 106 cells/ml. Cells were first blocked with TruStain FcX™
PLUS (anti-mouse CD16/32) and stained with FITC anti-mouse F4/80 Recombinant Antibody.
FITC Mouse IgG1,κ was used as isotype control. Cells were analyzed on a Guava easycyte (Luminex). The final BMDM cells were 98.8% F4/80 positive.

2.3.8

BMDM polarization in vitro.
BMDM cells were plated into 6 well plates at a density of 0.9x106 in RPMI 1640 medium

supplemented with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin, and 20ng/mL
murine M-CSF (Peprotech) at 37°C with 5% CO2 . After overnight culture, the non-treatment and
zymosan-adenovirus group cells were changed to fresh medium, whereas tumor conditioned medium
group cells were changed with mixture of regular BMDM medium and tumor conditioned medium
(1:1 ratio) plus 20 ng/ml of murine IL-4 (Peprotech). For LPS treatment group, cells were changed
to BMDM medium supplemented with 100 ng/ml of ultrapure LPS from E. coli 0111:B4 strain
(Invivogen). For zymosan-adenovirus conjugate treatment, conjugates at a ratio of 5 conjugates/cell
(50 viral particles/zymosan particle) were added into the designated wells and mixed well. Cells
were continued to culture for 48 hours.
At the end of culture, supernatants were collected and frozen down for cytokine ELISA.
Cells in one well from each group were used for RNA extraction and one well for protein extraction.
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2.3.9

Tumor Conditioned Media (TCM).
B16 cells were trypsinized and cultured in 6-well plates at a concentration of 2x105 cells/well.

To prepare 2x concentrated tumor conditioned medium, 1 ml of culture medium was used per well
instead of 2 ml. After overnight culture, medium was collected and centrifuged at 250xg for 5min
to remove detached B16 cells. Supernatant was filtered through a 0.22 µm filter for immediate use
or aliquoted and frozen down for subsequent use.

2.3.10

RNA Isolation and qRTPCR.
RNA was isolated from BMDM/RAW cell culture using Trizol reagent (Invitrogen). Con-

centration and purity of the isolated RNA was determined using NanoDrop One (Thermo Fisher).
One thousand nanograms of RNA were reverse transcribed using GoScript™ Reverse Transcription
Mix (Promega) or reverse transcriptase (Cat. No. K1071) protocol (APExBIO). Real time qPCR
reaction was performed in 96 well plates on a CFX96 Real Time System (Bio-Rad) using Quanitfast® SYBR® Green mix (Qiagen) and primers in biological triplicate and technical duplicate
(Table 2.1). Relative gene expression was calculated using the DDCT method, GAPDH or β-actin
were used as the reference gene. Normal conditioned BMDMs or RAW 264.7 cells were used as the
reference group.
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Gene

Forward Primer

Reverse Primer

GAPDH

F:CCCTTAAGAGGGATGCTGCC

R:ATGAAGGGGTCGTTGATGGC

β-actin

F:GGCTGTATTCCCCTCCATCG

R:CCAGTTGGTAACAATGCCATGT

MHC II I-A β 1

F:GTGGTGCTGATGGTGCTG

R:CCATGAACTGGTACACGAAATG

Il-1α

F:TCAGCACCTTACACCTACC

R:GCAACTCCTTCAGCAACAC

CD163

F:GCCCAACTTCTATTAAAGCCC

R:TGTTCACCAGTCTCATCTCC

CD86

F:TTCCTCCAAACCTCTCAATTTC

R:TCTCTCTGTCAGCGTTACTATC

CD206

F:TCCACTCTATCCACCTTCAC

R:TCTTCACAACTCAAAACATCCC

NOS2

F:CCCAACAATACAAGATGACCC

R:CAAAATCTCTCCACTGCCC

CXCL1

F:CCAAACCGAAGTCATAGCC

R:TGGGGACACCTTTTAGCATC

CXCL2

F:CTGTCAATGCCTGAAGACC

R:GCAAACTTTTTGACCGCC

Arg1

F:AAGACAGGGCTCCTTTCAGG

R:CGTTGAGTTCCGAAGCAAGC

Irg1

F:ATGGGATGGAAGCCACGTTT

R:TGCCGGGAAGCTCTTAAAGG

Aco2

F:ATAGCCTGTCCCACCTACCC

R:GCAGTGTGGTTCCTCTACCC

IL-10

F:GCTGGACAACATACTGCTAACC

R:ATTTCCGATAAGGCTTGGCAA

IL-12

F:CCTCCTCACACAGATAGGAAAC

R:GAGATGAGATGTGATGGGAGAAC

Table 2.1: In Vitro Primers

2.3.11

Western Blot.
For Western blot analysis, cells from different treatment groups were trypsinized and nu-

clear protein was extracted based on a previously published procedure with nuclear extraction buffer
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(HEPES [20 mM] pH 7.9, NaCl [0.4 M], EDTA [1 mM], Glycerol 25%, Protease Inhibitors 1x) [Osborn et al., 1989]. Extracted protein was quantified using a Bradford assay kit according to the
manufacturer’s protocol (Fisher Scientific). For Western blot analysis, 1 ug of lysate proteins were
loaded on to a 10% SDS-PAGE gel and transferred onto PVDF membranes. The membranes were
incubated overnight at room temperature with one of the following: anti-NFκB, anti-p-NFκB p65
Antibody (Ser 536), anti-pSTAT1, or anti-STAT1 (Santa Cruz) followed by incubation with HRP
conjugated goat anti-mouse antibody for one hour. The membranes were developed with WesternSure® PREMIUM Chemiluminescent Substrate and the images were recorded with a C-digit Blot
Scanner (Li-Cor). The membranes were stripped with WesternSure® ECL Stripping Buffer and
re-probed with Anti-β-Actin Antibody (AC-15).

2.3.12

Enzyme-Linked Immunosorbent Assay.
After the indicated treatments, the supernatants were collected, and an ELISA analysis was

performed to detect the expression level of IL-12p70 (Cat No. 433604) using the ELISA Max Delex
set according to the manufacturer’s protocol (Biolegend). Expression of IL-10 was quantified using
the ELISA Mx standard set (Cat No. 431411) according to the manufacturer’s protocol (Biolegend).

2.3.13

Statistical Analysis.
Statistical Analyses were performed using GraphPad Prism 9. The data were presented with

+/- standard deviation. Semi-quantification of western blotting was analyzed using ImageJ software
(NIH). Comparisons between groups/conditions were analyzed using ANOVAs followed by Tukey’s
test. P<0.05 was considered to indicate a statistically significant difference. Biological triplicates or
duplicates were used.
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2.4
2.4.1

Results
Zymosan:Adenovirus Encoding IRFs therapy design
This study investigated the potential of a phagocytic-directed immunomodulatory therapy

via zymosan conjugated recombinant adenoviruses encoding constant active forms of interferon regulatory factor 3 (IRF3) and 7 (IRF7) to alter TAM phenotype and induce local and systemic immune
favorable conditions. Adenoviruses were chosen based on their transient gene expression and use in
cancer gene therapy. Recombinant adenoviruses were designed to encode constant active forms of
IRF3 and IRF7. Phosphomimetic, active forms of IRF3 were induced through an aspartate substitution at a serine residue in the C-terminal (S396D) (Figure 2.1). Mutagenesis at this phosphorylation
site is sufficient for IRF3 activation [Lin et al., 1998]. Active forms of IRF7 were induced by deleting
the autoinhibitory domain(∆238-410) in the C-terminal (Figure 2.1). This deletion also negated the
need for activation via phosphorylation in the C-terminal of IRF7 [Romieu-Mourez et al., 2006].

Figure 2.1: Mutagenesis of IRF3 and IRF7

Adenoviruses were conjugated to zymosan particles via streptavidin/biotin conjugation (Figure 2.2). First, streptavidin was conjugated to zymosan particles as described in materials and
methods. Zymosan-streptavidin particles were fully saturated with biotinylated anti-adenovirus an43

Figure 2.2: Zymosan Adenovirus Conjugation
tibodies. Before each experiment, specified amounts of adenovirus were added accordingly. Zymosan
particles were chosen to enhance uptake by phagocytic cells and for additional induction of a proinflammatory immune response [De Graaff et al., 2021, Liu et al., 2015].
To confirm that the recombinant adenovirus encodes IRF3 that can effectively be transcribed
and translated in mammalian cells, AD293 cells were directly infected with Ad IRF3 (Figure 2.4A).
NIH/3T3 cells have a natural high expression of IRF3 and thus were used as a positive control.
Through immunoblotting an increase in IRF3 protein expression in the AD293 following Ad IRF3
expression indicated that the gene of interest was effectively transcribed and translated. Further, a
recombinant adenovirus encoding GFP was used to compare uptake between AD293 and RAW 264.7
cells (Figure 2.4B). These results suggested that adenovirus infection and expression was similar in
AD293 and RAW 264.7 cells.
Since zymosan and adenovirus are both pro-inflammatory, immunomodulatory agents, a
zymosan:adenovirus conjugate encoding GFP (Zym:Ad GFP) was used to distinguish differences
induced by the delivery particle and the genes of interest, IRF3 or IRF7. Further, Zym:Ad GFP
was used to observe transfection efficiency in macrophages. Specifically, murine macrophage cells,
RAW264.7, transfected with Zym:Ad GFP particles for 48 hours were imaged and uptake was
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(A)

(B)

Figure 2.3: Zym:Ad uptake is higher in RAW264.7 cells than in B16 cells in vitro A. Flow cytometric
analysis of RAW 264.7 cells following 48 hours of infection with Zym:Ad GFP (1:1 ratio of conjugate
particles/cell) B. Flow cytometric analysis of B16 cells following 48 hours of infection with Zym:Ad
GFP (1:1 ratio of conjugate particles/cell)
determined to be about 80% (Figure 2.4C). High uptake of Zym:Ad GFP by macrophages is critical
in our investigation into TAM reprogramming, as macrophages tend to be notoriously difficult to
transfect.
Macrophage uptake was determined by comparing Zym:Ad GFP uptake in RAW 264.7 cells
and B16 cells. 48 hours post infection with Zym:Ad GFP at a 1:1 ratio, cells were analyzed using
flow cytometry. Results show that macrophage uptake was 12 times higher than B16 uptake 2.3.
These findings support that the Zym:Ad conjugate particle is directed toward macrophages, but still
may be taken up by other cells to a certain degree.
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(B)

(A)

(C)

Figure 2.4: IRF3 Expression in AD293 and Uptake of Zym:Ad GFP in RAW 264.7 Cells. A.
IRF3 expression from whole cell lysates was quantified via western blot following 48 hours of Ad
IRF3 infection of AD293 cells (MOI 250). NIH/3T3 cells were used as a positive control for IRF3
expression. β-Actin was used as the housekeeping control (not pictured). B. Fluorescent images
of GFP expression in AD293 and RAW 264.7 cells following 48 hours of infection with Ad GFP
(MOI 250) indicate comparable uptake. C. Uptake of Zym:Ad GFP expression in RAW 264.7 cells
following 48 hours of infection was quantified using fluorescence microscopy and ImageJ (NIH)
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(B)
(A)

Figure 2.5: Schematic of TAM-like BMDM conditioning and purity of BMDMs. A. BMDMs were
stained with FITC anti-mouse F4/80 and analyzed on a Guava easycyte to determine purity. FITC
Mouse IgG1,κ was used as isotype control. B. Subsequent conditioning of BMDMs for M0, M1, M2
controls in addition to experimental groups treated with one of three zymosan-adenovirus conjugate
particles.

2.4.2

TAM-like BMDM Conditioning and Purity
Throughout the in vitro experiments, bone marrow derived macrophages were conditioned

to resemble TAMs. BMDMs were differentiated from bone marrow monocytes as described in
materials and methods. The purity of BMDMs was determined through flow cytometric analysis of
macrophage marker, F4/80. The final BMDM cells were 98.8% F4/80 positive (Figure 2.5A).
BMDMs were cultured in B16 tumor conditioned media and interleukin-4 (IL-4) for 24
hours to induce a TAM-like phenotype. TAM-like BMDMs were then treated with Zym:Ad IRF3 or
Zym:Ad GFP particles (5 conjugate particles/cell; 50 viral particles/zymosan) for 48 hours. Zym:Ad
GFP was used to distinguish differences in gene expression caused by the Zym:Ad delivery particle
and the genes of interest, IRF3 and IRF7. Normal conditioned BMDMs were used as the reference
group. Untreated, TAM-like BMDMs were used as the M2 control and LPS-conditioned BMDMs
were used as an M1 control (Figure 2.5B). Our classification of macrophages included analysis of
relative gene expression, cytokine expression, and transcription factor expression to evaluate the
shift from M2-like to M1-like TAMs in vitro.
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2.4.3

Zymosan:Adenovirus Induces M1-like Phenotype in TAM-like BMDMs
in vitro
Relative gene expression of TAM-like BMDMs treated with all three Zym:Ad treatments

indicated upregulation of M1-like genes, CD86, TNFα, IL-12, MHC II, and IL-1α, IFNα, (Figure
2.6A) and down regulation of M2-like genes, CD163, CD206, and IL-10, (Figure 2.6B). Compared to
the Zym:Ad GFP control, IL-1α, pro-inflammatory cytokine that increases inflammation in neighboring cells [Cavalli et al., 2021], expression was greater in Zym:Ad IRF3 and Zym:Ad IRF7 treated
TAMs. Compared to the M0 control group relative gene expression of CD86, classic M1 marker,
was significantly upregulated in all three Zym:Ad treated TAMs with the highest upregulation in
Zym:Ad IRF7 treated TAMs. Further MHC II, indicative of antigen presenting to CD4 helper T
cells, gene expression was greater in Zym:Ad IRF3 and Zym:Ad IRF7 treated TAMs compared
to the Zym:Ad GFP control. The same trend was observed in IL-12, pro-inflammatory cytokine
involved in T cell production of IFNγ, gene expression. CD206 is a common surface receptor associated with immune homeostasis and thus potentially immunosuppression in the TME [Haque et al.,
2019]. CD163 binds haptoglobin-hemogolbin complexes and induces an anti-inflammatory response
involving secretion of IL-10 [Skytthe et al., 2020]. CD163 and CD206, also classic M2 markers,
gene expression decreased in all three Zym:Ad treated TAM-like BMDMs. IL-10, immunosuppressive cytokine, was downregulated in all three Zym:Ad treatments with a higher downregulation in
Zym:Ad IRF7 treated TAM-like BMDMs. On the whole all three Zym:Ad treatments upregulated
M1-like gene expression and downregulated M2-like gene expression with few statistical differences
in relative gene expression between Zym:Ad GFP, Zym:Ad IRF3, and Zym:Ad IRF7.
The pro- and anti-tumor effects of TAM metabolism are complex [Mazzone et al., 2018].
Relative gene expression of metabolic markers (Arg1, iNOS, and Irg1) in TAM-like BMDMs were analyzed to gain insight into glucose and arginine metabolism (Figure 2.6C). Overall, Zym:Ad induced
downregulation of Arg1 and upregulation of iNOS and Irg1 gene expression. Arginine can either be
metabolized by inducible nitric oxide synthase (iNOS) or hydrolyzed by Arginase 1 (Arg1). M2-like
TAMs have higher expression of Arg1 and M1-like TAMs have higher expression of iNOS. TAM-like
BMDMs treated with Zym:Ad GFP, Zym:Ad IRF3, and Zym:Ad IRF7 had significantly downregulated Arg1 and upregulated iNOS expression compared to the untreated TAM-like BMDMs. IRG1,
enzyme involved in converting cis-aconitate to itaconate, was significantly upregulated in Zym:Ad
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IRF3 but not in Zym:Ad GFP or Zym:Ad IRF7.
To investigate alterations in cytokine secretion at the protein level, supernatant expression
of pro-inflammatory (IL-12) and anti-inflammatory (IL-10) were quantified using ELISA (Figure
2.7). IL-12 is a signature cytokine of an M1 and Th1 immune response, whereas IL-10 is a signature
cytokine of an M2 and Th2 immune response. Zym:Ad GFP and Zym:Ad IRF3 treated BMDMs
increased secretion of IL-12 and decreased secretion of IL-10 compared to the TAM-like BMDM control (Fig. 2E). Further IL-12 concentration in Zym:Ad IRF3 treated BMDMs was 1.4 times greater
than in Zym:Ad GFP treated BMDMs. IL-10 concentration in Zym:Ad IRF3 treated BMDMs was
1.7 times less than in Zym:Ad GFP treated BMDMs.
Transcription factor expression was quantified using immunoblotting. Western blot analysis
of phosphorylated NF-κBp65 and STAT1 further suggest that Zym:Ad GFP and Zym:Ad IRF3
shift TAM-like macrophages toward M1-like. NF-κB activation is well known for its involvement
in TAM polarization from M2-like to M1-like (Zheng et al. 2017). Zym:Ad GFP and Zym:Ad
IRF3 increased phosphorylated NF-κBp65 by 21 and 25 times, respectively, compared to TAM-like
BMDMs (Figure 2.8A and Figure 2.8B). Phosphorylation of STAT1 enhances expression of M1associated genes including NOS2, IL-12, and MHCII, all of which support an immune favorable
TME [Mancino and Lawrence, 2010]. Zym:Ad GFP and Zym:Ad IRF3 increased phosphorylated
STAT1 by 3.2 and 2.6 times, respectively, compared to TAM-like BMDMs (Figure 2.8Cand Figure
2.8D). Together these results suggest that Zym:Ad GFP and Zym:Ad IRF3 shift TAMs toward an
M1-like state in vitro.
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(A)

(B)

(C)

Figure 2.6: Zymosan:Adenovirus alters gene expression in TAM-like BMDMs in vitro
TAM-like conditioned BMDMs treated with Zym:Ad GFP (TC+GFP), Zym:Ad IRF3 (TC+IRF3),
Zym:Ad IRF7 (TC+IRF7) for 48 hours were analyzed for relative gene expression. A. Total RNA
was isolated and M1 gene expression (CD86, TNFα, IL-12, MHC II IA, Il-1α) was determined by
qRTPCR analysis B. Total RNA was isolated and M2 gene expression (CD163, CD206, IL-10) was
determined by qRTPCR analysis. C. Total RNA was isolated and metabolic gene expression (Arg1,
iNOS, Irg1) was determined by qRTPCR. Heatmaps were created using Log2 transformed relative
gene expression values in biological triplicate, technical duplicate.
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Figure 2.7: Zymosan:Adenovirus Alters Cytokine Secretion by TAM-like BMDMs in
vitro. Supernatant from TAM conditioned and treated BMDMs was used for ELISA (IL-12, IL-10).
Compared with the M2:TC control group, p<0.01; compared with the TC+GFP group, #p<0.01.
Results are +/- SD of biological duplicate, technical duplicate.
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(B)

(A)

(D)
(C)

Figure 2.8: Zymosan: Adenovirus alters Transcription Factor Expression from M2-like
to M1-like in TAM-like BMDMs in vitro Nuclear extracts were prepared from TAM-like
BMDMs with and without treatments, quantified using the Bradford Assay, and 1µg was used for
chemiluminescent western blot analysis of A. phosphorylated NF-κB p65 with NF-κB control protein
B. Quantification of B using fold change of adjusted pNF-κBp65 signal/adjusted NF-κB signal C.
pSTAT1 with STAT1 control protein D. Quantification of C using fold change of adjusted pSTAT1
signal/adjusted STAT1 protein signal. Western blots were only done once.
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2.5

Discussion
In this study, it was determined that the zymosan-adenovirus conjugate particle, regardless

of encoding IRF3 or IRF7, induced a shift from M2-like to M1-like phenotype in TAM-like BMDMs
in vitro as indicated by changes in relative gene expression, cytokine secretion, and transcription
factor expression. All three Zym:Ad treatments altered M1-like and M2-like gene, cytokine, and
transcription factor expression in a similar manner with few differences between the three treatments,
suggesting that the Zym:Ad particle itself is sufficient for shifting TAMs from pro-tumor to antitumor in vitro.
Macrophages are notoriously hard to transfect or transduce, due to their role as first responders to foreign or exogeneous material [Keller et al., 2018]. Therefore the high uptake of Zym:Ad
GFP achieved by RAW 264.7 cells in this study is biologically significant. Finding the balance
between uptake efficiency and cytotoxicity was critical to the design of the chosen ratios for the
zymosan-adenovirus conjugates, and the limiting factor in forming the conjugate particles was the
cytotoxicity of the adenoviruses. Previous research shows that MOI 250 for adenovirus 5 (∆ E1 and
E3) for transfection of mouse bone marrow derived cells does not induce significant cytotoxicity [Zhu
et al., 2007]. Further our results showed that zymosan did not alter cytotoxicity up to 20:1 ratio
with murine macrophage cell line, RAW 264.7 (Supplemental Figure 2.9), thus theoretical ratios of
5:1 zymosan:macrophage and 250:1 adenovirus:macrophage were used to calculate the amounts of
adenovirus and zymosan to conjugate before each experiment.
The biotin-streptavidin conjugation of zymosan and adenovirus particles resulted in exposure of both zymosan, β-1,3-glucans, and adenoviruses; therefore, the particle could have been taken
up via zymosan or adenovirus. The uptake mechanism of the Zymosan:Adenovirus conjugate could
be investigated in vitro by inhibiting respective receptors for zymosan and adenovirus and comparing
uptake of Zym:Ad GFP. If the Zym:Ad conjugate is taken up by zymosan, inhibiting Dectin-1 would
decrease uptake of Zym:Ad GFP. If the Zym:Ad conjugate is taken up by adenovirus, then inhibiting
scavenger receptors (e.g., MARCO, SR-A, SREC1) would decrease its uptake in macrophages [Maler
et al., 2017]. Understanding the uptake mechanism would give insight into TAM-specificity in vivo,
which will be discussed in more detail in the next chapter.
The Zymosan:Adenovirus conjugate particle was designed to be a phagocytic cell directed
immunomodulatory therapy. Zymosan, or other forms of β-glucans, are commonly used in TAM-
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targeted delivery, and this study showed higher uptake in macrophages, RAW264.7 cells, compared
to B16 tumor cells in vitro [Zhang et al., 2015, Su et al., 2021]. In this experiment cells were infected with a 1:1 ratio; however, experiments involving phenotypic analysis were conducted using
a 5:1 ratio. This lower ratio was chosen for flow cytometric analysis due to issues with nonphagocytized Zym:Ad particles clogging the flow chamber. Further, RAW cells were used due to limited
availability of mouse derived BMDMs. GFP expression in BMDMs was similar to GFP expression
quantified and observed in RAW cells. In summary, these GFP uptake results indicate that the
Zym:Ad GFP particle is more readily taken up by macrophages than B16 cells. However, it does
not demonstrate preferential uptake, which could be determined by GFP expression analysis of a
co-culture experiment with BMDMs and B16 cells infected with Zym:Ad GFP.
In this study, phenotypic changes in macrophages were analyzed 48 hours after infection.
This time point was chosen based on a few different factors. First, using Zym:Ad GFP as a control, GFP expression was observed at 12 hours, 24 hours, 48 hours, and 72 hours post infection.
There was no GFP expression before 24 hours, and high GFP expression at 48 hours and 72 hours.
However, these observations were made in RAW 264.7 cells with high proliferation rates and by
72 hours, cells were beginning to get overcrowded. Overcrowding alters RAW cell phenotype and
thus made it difficult to distinguish differences induced by overcrowding and our treatment. Thus,
48 hours post infection was chosen as the best time to analyze phenotypic changes induced by the
Zym:Ad treatments. In BMDMs observed a similar pattern of GFP expression was observed, thus
for consistency analyses were also conducted 48 hours post infection. By conducting a more detailed
analysis of IRF3 and IRF7 protein expression, instead of GFP expression, from nuclear extracts
of infected RAW or BMDMs, an alternative length of time post infection to analyze phenotypic
changes may be determined. The optimal time would be shortly after peak expression of IRF3 and
IRF7, in order to allow ample time for IRF3 and IRF7 to induce transcription of their target genes.
The lack of impact by the genes of interest, IRF3 and IRF7, is surprising and should be
further investigated. Quantifying and comparing IRF3 and IRF7 protein expression following all
three Zym:Ad treatments could give insight into this finding. Although possibly more substantial
would be to quantify the amount of IRF3 and IRF7 actively interacting with interferon stimulated
response elements (ISREs) in the nucleus. This could be analyzed through co-immunoprecipitation
and would allow us to determine if Zym:Ad itself already maximizes IRF3 and IRF7 transcription
activity due to its natural pro-inflammatory effects.
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TAM reprogramming of M2-like to M1-like phenotype does not necessarily translate to
inducing an anti-tumor TAM phenotype. Most data supports that higher M1 expression in the TME
is associated with good prognosis; however, there are some contexts in which higher expression of
M1 macrophages does not improve prognosis [Oshi et al., 2020]. Contradictory research strictly
comparing M1 and M2 surface expression elucidates a discrepancy in the evaluation of anti-tumor
TAMs (i.e., M1 phenotype is not always equivalent to anti-tumor phenotype). In this study, genes,
proteins, and transcription factors were chosen based on their influence on pro-tumor or anti-tumor
function. All of the pro-tumor markers aligned with an M2-like phenotype and all of the anti-tumor
markers aligned with an M1-like phenotype. Throughout this study, the M2-like signature was
defined by increased expression of CD206, CD163, Arg1, and IL-10. The M1-like signature was
defined by increased expression of CD86, MHC II, iNOS, IL-12, pNF-κBp65, and pSTAT1 (Figures
2.5-2.7). Thus, these phenotypes can also be referred to as pro-tumor and anti-tumor.
This research supports a phenotypic shift from pro-tumor TAMs to anti-tumor TAMs. Functional assays to determine direct and in-direct TAM anti-tumor function can further elucidate this
shift. This research did not focus on the interaction between TAM and tumor cells; however, research shows that reprogramming TAMs can induce direct cytotoxicity [Pan et al., 2020]. Cytostatic
or cytotoxic assays could be used to determine if Zym:Ad treated TAMs could directly stop tumor
proliferation or induce tumor death, respectively [Oliveira et al., 2019]. Another direct anti-tumor
function of TAMs is their ability to phagocytose tumor cells. Often tumor cells inhibit phagocytosis
through expression of various ligands (e.g., PD-L1, CD47) [Ge and Ding, 2020]. Phagocytosis of
fluorescently labeled tumor cells can be analyzed through flow cytometry or fluorescnet microscopy
[Nam et al., 2019]. Another reason that M2-like TAMs are considered to be pro-tumor is their role
in promoting metastasis through secretion of VEGF and MMPs. Their angiogenic function can be
assessed through an in vitro CAM assay [Movahedi et al., 2010].
The immunosuppressive TME creates a challenge for current immunotherapies. The degree
to which M2-like TAMs contribute to that immunosuppression is significant [Wang et al., 2021].
More importantly, the anti-tumor functions of M1-like TAMs have been elucidated, making TAM
reprogramming a promising strategy to reverse immunosuppression in the TME [Zhuang et al., 2020,
Han et al., 2021]. Here, the potential of zymosan conjugated with adenovirus to reprogram TAMs
was explored. Both zymosan and adenovirus are pro-inflammatory stimulants that induce a shift
from M2-like to M1-like macrophages, but they each have their limitations as independent agents.
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The adenovirus is one of the most common gene delivery vectors for cancer therapy; however, high
doses of adenovirus induce undesired systemic toxicity thus limiting its efficacy as a monotherapy
for TAM reprogramming [Hassan et al., 2018]. Zymosan is a naturally occurring substance and has
negligible cytotoxic effects making it readily available and safe for clinical treatment [Chan et al.,
2009]. This study did not focus on the effects of zymosan to reprogram TAMs, but rather the purpose
of zymosan was to more directly deliver adenovirus to phagocytic cells in vivo. In this study, zymosan
conjugated with adenoviruses altered gene expression, cytokine expression, and transcription factor
expression toward an M1-like, anti-tumor phenotype in TAM-like BMDMs suggesting its potential
as an immunomodulatory therapy.
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2.6

Supplementary Data

Figure 2.9: Zymosan Cytotoxicity in RAW 264.7 Cells. RAW 264.7 cells were seeded in 96 well plate
and left overnight. Zymosan at indicated ratios were added for 24 hours. Using Aqueous One Cell
Proliferation Assay, we determined that zymosan did not affect cell proliferation at the indicated
ratios. One biological replicate, technical triplicate.
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Figure 2.10: Nitric Oxide Production in BMDMs. Using a nirate/nitrite assay, total NO concentration was measured in supernatant of BMDMs conditioned and treated as previously described. One
biological replicate, technical triplicate.
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Figure 2.11: Individual Counts of Relative Gene Expression as shown in heatmaps in Fig 2.5.
Compared with the M2:TC control group, p<0.01; compared with the TC+GFP group, #p<0.01.
Results are +/- SD of biological triplicate, technical duplicate.
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Chapter 3

Therapeutic Effects of
Intratumoral Injection of Zymosan
Conjugated Adenovirus Encoding
IRF3 and IRF7 in vivo
3.1

Abstract
An immunosuppressive tumor microenvironment (TME) leads to cancer growth, metasta-

sis, and therapeutic resistance thus immunomodualtory therapies that induce a localized shift in
anti-tumor activity while still inducing a systemic anti-tumor immune response has great potential
in solid tumors. In this study, intratumoral injection of recombinant adenoviruses encoding active
forms of interferon regulatory factor 3 (IRF3) and interferon regulatory factor 7 (IRF7) were conjugated to zymosan particles to target phagocytic cells directly in the TME. The focus of this study
was to determine if the phenotypic changes observed in tumor-associated macrophages (TAMs)
in vitro translates to an in vivo setting. The model used in this study was a double tumor B16
melanoma mouse model, commonly used to analyze systemic tumor immunity in IT injection therapies. B16 melanoma is one of the most common metastatic melanoma models used for pre-clinical
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studies. Further, it has an immune-suppressed TME that is characteristic of therapy resistance in
many solid tumors. The overall shift to immune favorable conditions in the TME was suggested
by changes in metabolic, cytokine, and immune cell gene expression. Our data indicated that the
zymosan:adenovirus (Zym:Ad) particle itself induced a shift from M2-like to M1-like TAMs, a shift
in immune status of the TME, and systemic tumor immunity. Notably, direct intratumoral injection
of Zym:Ad IRF3 reduced tumor growth more significantly than Zym:Ad GFP, indicating additional
therapeutic benefits due to incorporation of constant active IRF3. This study provides the groundwork for future studies to explore potential combination therapies that could benefit from a boost
in immune activity in the TME.

3.2

Introduction
Immunomodulatory therapies have been used for over 100 years, dating back to the first

immunotherapy developed by William B. Coley (Coley’s Toxins) in the 1890s. Immunotherapy has
made huge strides in recent years, and yet researchers continue to come back to the potential of
pro-inflammatory agents to induce immune favorable conditions in the TME. Instead of injecting
live bacteria, researchers have now explored the efficacy of attenuated bacteria, replicative-deficient
viruses, cytokines, and immune checkpoint inhibitor immunomodualtory therapies. The most recent
breakthrough involving immune checkpoint blockades prevents tumor cells from deactivating CD8 T
cells thus allowing for potent anti-tumor CD8 T cell activity. Yet, immunotherapy is only effective
in 15-20% of these patients. One of the main contributing factors to this low efficacy is the immune
composition of the TME.
The immune status of the TME is a significant indicator of therapeutic response and tumor
progression. Tumors can be classified as immune-infiltrated, immune-suppressed, immune-excluded,
or immune desert. The most favorable immune TME is the immune-infiltrated, commonly referred to as a ”hot” tumor, due to infiltration of Th1 immune cells, specifically CD8 T cells.
Immune-suppressed, immune-excluded, and immune desert TMEs all present challenges for current immunotherapies that rely on existing CD8 T cell infiltration. In this study, the focus was on
altering the immune status of an immune-suppressed TME, B16 melanoma.
Immune-suppressed TMEs lack CD8 T cells and instead are occupied by immunosuppressive immune cells such as M2-like TAMs, Treg cells, and myeloid derived suppressor cells. Thus,
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administration of CD8 T cell focused immunotherapies to patients with immune-suppressed tumors
is typically ineffective. M2-like TAMs in particular have been under scrutiny for being a major proponent of the immunosuppression and reduced efficacy of immunotherapies; however, research has
shown that a higher ratio of M1:M2 TAMs is associated with immune favorable conditions and good
prognosis. Thus, immunomodulatory therapies that alter TAM phenotype are being investigated to
reverse immunosuppression and enhance efficacy of immunotherapies, such as immune checkpoint
blockades.
In this study, the immunotherapeutic effects of zymosan-adenovirus conjugates encoding
constant active forms of interferon regulatory factor 3 (IRF3) and 7 (IRF7) were investigated in a
double tumor melanoma mouse model. Alterations in the immune status of the TME were determined by analysis of TAM phenotype, cytokine/chemokine gene expression, metabolic gene expression, and T cell specific gene expression. Systemic tumor immunity was determined by the untreated
tumors in the double tumor model as well as a splenocyte proliferation assay. Anti-tumor activity
was indicated by tumor growth curves of both treated and untreated tumors.

3.3
3.3.1

Materials and Methods
Recombinant adenovirus construction, production, amplification,
purification, and quantification.
As described in Chapter 2 materials and methods.

3.3.2

Recombinant adenovirus IRF3 expression in vitro.
As described in Chapter 2 materials and methods.

3.3.3

Zymosan adenovirus conjugation.
As described in Chapter 2 materials and methods.
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3.3.4

Cell culture.
As described in Chapter 2 materials and methods.

3.3.5

Animal model.
C57BL/6 mice (10-12 weeks old) were inoculated with 1x105 B16 cells subcutaneously on

both the right and left abdomen. Ten days after inoculation, mice were treated with the first of
three doses. Each dose consisted of 50 µL of zymosan conjugated adenovirus suspended in PBS
(1x108 viral particles conjugated with 2x106 zymosan particles). Doses were administered on day
10, 14, and 21. Tumor measurements were taken with a vernier caliper before each dose as well as
on the day the tumor was harvested (day 29). Tumor volume was calculated using the following
equation: tumor volume = (l x w2 )/2 (Yuan2017). Treatments were administered intratumorally
in the right tumor. The left tumor was left untreated and monitored for growth as an indicator of
systemic tumor immunity. Control groups were inoculated and untreated.

3.3.6

Tumor Tissue Processing.
Tumor tissue was harvested on day 29. Tissue was either immediately transferred to -80°C

until use (50mg for RNA) or processed with enzymatic digestion for single cell suspension. Briefly,
tumors were finely chopped and suspended in DMEM 5% FBS. Tumors were digested with 20 µg/ml
Liberase TL (Roche) and 400 µg/ml DNAse (Roche) for 30 min at 37°C with rotation then filtered
through a 40 µm mesh filter. Cells were resuspended in RBC lysis buffer for 10 min at room temperature. Single cell suspension from tumor tissue was either used immediately or frozen down in
90% FBS + 10% DMSO [Aguilera et al., 2016].

3.3.7

TAM Polarization Analysis
From the single cell suspension of tumor tissue, CD11b cells were first isolated with the

MojoSort™ Mouse CD11b Selection Kit (Biolegend) and LS Columns (Miltenyi Biotec) according to
the manufacturers’ protocols. The purity of the purified CD11b cells were about 70% based on flow
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cytometry analysis (data not shown). The purified CD11b cells were either labeled with PE-F4/80
and FITC-CD206 or PE-F4/80 and CD80 (Biolegend) antibodies with appropriate isotype controls.
Stained cells were analyzed with a Guava Easycyte system (Millipore).

3.3.8

Splenocyte Proliferation Assay.
Splenocytes were prepared according to a previously published protocol [Lim et al., 2016].

Briefly, spleens were placed in between two pieces of sterile 100 µm cell strainer mesh in a petri
dish containing 2 ml ice-cold RPMI supplemented with FBS. The spleens were mashed into very
fine parts using a 1 ml plunger. The cell suspension was transferred to a 15 ml tube and spun down
at 453g for 5 min at 4°C. The pelleted cells were resuspended in RBC lysis buffer and incubated at
room temperature for 3-5 minutes.
Splenocytes were co-cultured with B16 cells at varying effector to target cell ratios (40:1,
20:1, 10:1). After 24 hours ATP was quantified by CellTiter-Glo Luminescent Cell Viability Assay
according to the manufacturer’s protocol (Promega). Splenocytes were pooled from 3 spleens. Experiment was carried out in technical duplicates. Lytic units per spleen was calculated as described
(Bryant et al. 1992). Percent specific lysis was calculated using the following equation: % Lysis =
(100- ((Splenocytes+B16)- Splenocytes)/ B16) x 100.

3.3.9

RNA Isolation and qRTPCR.
RNA was isolated from tumor tissue following mechanical digestion using Trizol reagent

(Invitrogen). Concentration and purity of the isolated RNA was determined using NanoDrop One
(Thermo Fisher). One thousand nanograms of RNA were reverse transcribed using GoScript™ Reverse Transcription Mix (Promega) or reverse transcriptase (Cat. No. K1071) protocol (APExBIO).
Real time qPCR reaction was performed in 96 well plates on a CFX96 Real Time System (Bio-Rad)
using Quanitfast® SYBR® Green mix (Qiagen) and the following primers in biological triplicate and technical duplicate Table(3.1). Relative gene expression was calculated using the DDCT
method, GAPDH or β-actin were used as the reference gene. Inoculated, untreated mice were used
as the reference group.
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Gene

Forward Primer

Reverse Primer

β-actin

F:GGCTGTATTCCCCTCCATCG

R:CCAGTTGGTAACAATGCCATGT

CD86

F:TTCCTCCAAACCTCTCAATTTC

:TCTCTCTGTCAGCGTTACTATC

MHC II I-A β 1

F:GTGGTGCTGATGGTGCTG

R:CCATGAACTGGTACACGAAATG

Il-1α

F:TCAGCACCTTACACCTACC

R:GCAACTCCTTCAGCAACAC

CD68

F:CCCACCTGTCTCTCTCATTTC

R:CACATTGTATTCCACCGCC

CD80

F:ACACCACTCCTCAAGTTTCC

R:AGGAGAGTTGTAACGGCAAG

CD163

F:GCCCAACTTCTATTAAAGCCC

R:TGTTCACCAGTCTCATCTCC

CD86

F:TTCCTCCAAACCTCTCAATTTC

R:TCTCTCTGTCAGCGTTACTATC

CD206

F:TCCACTCTATCCACCTTCAC

R:TCTTCACAACTCAAAACATCCC

NOS2

F:CCCAACAATACAAGATGACCC

R:CAAAATCTCTCCACTGCCC

CXCL1

F:CCAAACCGAAGTCATAGCC

R:TGGGGACACCTTTTAGCATC

CXCL2

F:CTGTCAATGCCTGAAGACC

R:GCAAACTTTTTGACCGCC

MIF

F:GAGGGGTTTCTGTCGGAGC

R:GTTCGTGCCGCTAAAAGTCA

Arg1

F:AAGACAGGGCTCCTTTCAGG

R:CGTTGAGTTCCGAAGCAAGC

Irg1

F:ATGGGATGGAAGCCACGTTT

R:TGCCGGGAAGCTCTTAAAGG

Aco2

F:ATAGCCTGTCCCACCTACCC

R:GCAGTGTGGTTCCTCTACCC

Hif-1α

F:AGCCTTAACCTGTCTGCCAC

R:AGCGTATGTCAGAAAGTTGGCT

CD3

F:ATTTCTCGGAAGTCGAGGAC

R:AGGCGATGTCTCTCCTATCT

CD4

F:CTTCCCCCAAAACCCTAGTT

R:TCTCTCCATAAAGGACCCCA

CD8

F:TTGGCAGGCCTCAAGAATAA

R:GCCATTAGCTCATCTGGTCT

FoxP3

F:TGCCCATCTCTGTCTCAATC

R:GAAGTTGCTGCTTTAGGTGG

NcR1

F:ACCCCCTGAAACTGGTAGTA

R:TGGTTGGATCCTCTCTCCTT

IFN-γ

F:ATGAACGCTACACACTGCATC

R:CCATCCTTTTGCCAGTTCCTC

IL-10

F:GCTGGACAACATACTGCTAACC

R:ATTTCCGATAAGGCTTGGCAA

IL-12

F:CCTCCTCACACAGATAGGAAAC

R:GAGATGAGATGTGATGGGAGAAC

IL-2

F:TGAGCAGGATGGAGAATTACAGG

R:GTCCAAGTTCATCTTCTAGGCAC

F4/80 (ADGRE1)

F:ACAAGACTGACAACCAGACG

R:ACCAGCAGCGATTATGCATC

TNF-α

F:CCCTCACACTCAGATCATCTTCT

R:GCTACGACGTGGGCTACAG

Table 3.1: In Vivo Primers
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3.3.10

Statistical Analysis.
Statistical Analyses were performed using GraphPad Prism 9. The data were presented with

+/- standard deviation. Semi-quantification of western blotting was analyzed using ImageJ software
(NIH). Comparisons between groups/conditions were analyzed using ANOVAs followed by Tukey’s
test. P<0.05 was considered to indicate a statistically significant difference. Biological triplicates or
duplicates were used. Mixed-effects model was used for tumor growth curve analysis.
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3.4
3.4.1

Results
Zymosan:Adenovirus IRF3 and IRF7 reduce tumor growth and upregulated M1 associated genes in vivo
The observations from in vitro TAM reprogramming prompted investigation of the ther-

apeutic potential of Zym:Ad in vivo. C57BL/6 mice were subcutaneously inoculated with B16,
murine melanoma, cells in both the right and left abdomen (Figure 3.1A). 10 days after inoculation,
the right tumors were intratumorally injected with Zym:Ad with a series of three doses on day 10,
14, and 21 (Figure 3.1B). The left tumors were untreated to be used for systemic tumor immunity
analysis. To evaluate anti-tumor activity, a tumor growth curve was calculated for the treated tumors based on tumor measurements taken on days 10, 14, 21, and 29. By day 29, Zym:Ad IRF3
and Zym:Ad IRF7 treated tumors reduced tumor growth compared to untreated, control tumors
(Figure 3.2). The Zym:Ad GFP treated tumors were not statistically different in size compared to
the untreated, control tumors.
(B)
(A)

Figure 3.1: B16 Melanoma Mouse Model and Study Timeline A. Illustration of the double
tumor model. Mice were inoculated with 1x105 B16 cells (s.c.) in the right and left abdomen.
Throughout the course of the study, the right tumor was directly treated, and the left tumor was
left untreated to be used for systemic immunity analysis. B. In vivo study timeline consisted of a
series of three Zym:Ad intratumoral injections (1x108 adenovirus particles; 2x106 zymosan particles;
50µL/dose).
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Figure 3.2: Zymosan:Adenovirus IRF3 and IRF7 reduces tumor growth in B16 melanoma
model Tumor volume growth curve on the treated (right) tumor calculated from tumor length and
width measurements taken on days 10, 14, 21, and 29. Compared with control group, p<0.001; ×
p<0.01; N=5.
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To investigate whether this reduced growth was accompanied by changes in TAM infiltration
and phenotype, tumor homogenate was evaluated for relative gene expression of multiple macrophage
markers (Figure 3.3). In Zym:Ad IRF3 treated tumors, macrophage lineage marker, F4/80, relative
gene expression was 109 times greater than the untreated control tumor and 27 times greater than
the Zym:Ad GFP treated tumors. CD206 is a common surface receptor associated with immune
homeostasis and thus potentially immunosuppression in the TME [Haque et al., 2019]. CD163 binds
haptoglobin-hemogolbin complexes and induces an anti-inflammatory response involving secretion of
IL-10 [Skytthe et al., 2020]. CD163 and CD206, also classic M2 markers, gene expression indicated
downregulation in all three Zym:Ad treated tumors with the greatest downregulation in Zym:Ad
IRF3. CD80, M1-like macrophage co-stimulatory surface marker, was significantly upregulated in
Zym:Ad IRF3 (66 times) and was also upregulated in GFP (7.5 times). Zym:Ad IRF7 increased
expression of CD80 and decreased expression of CD163 and CD206, but not as significantly as
Zym:Ad IRF3 or Zym:Ad GFP.
Surface expression of TAMs was evaluated to determine if the changes in gene expression
translated to differences at the protein level. CD11b+ cells were isolated, as described in materials and methods, from single cell suspension from tumor tissue. Next, double staining was
used to identify changes in M1-like and M2-like TAM populations (Figure 3.4). All three Zym:Ad
treated tumors had decreased infiltration of CD11b+ F4/80+ CD206+ cells and increased infiltration
of CD11b+ F4/80+ CD80+ cells. Taken together, upregulation of M1-like TAMs and downregulation
of M2-like TAMs were induced by the Zym:Ad particle itself in vivo; however, Zym:Ad IRF3 induced
a more potent therapeutic effect indicated by reduced tumor growth.

69

Figure 3.3: Zymosan:Adenovirus Alters TAM phenotype in vivo in Treated Tumors
RNA was extracted from treated (right) tumor tissue homogenate using Trizol and qRTPCR was
performed to analysis relative gene expression using the DDCT method. A. Relative gene expression
of F4/80 was analyzed to gain insight into macrophage infiltration in the TME B. Relative gene
expression of M1(CD80) vs. M2 (CD163, CD206). Error bar indicates range of technical duplicates.
Samples were pooled from 3-5 mice per group- one biological replicate.
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(A)

(B)

Figure 3.4: Zym:Ad Alters TAM Surface Expression in vivo CD11b+ cells were isolated from
single cell tumor suspensions and were labeled with A. PE-F4/80 and FITC-CD206 antibodies to
quantify changes in M2-like TAMs or B. PE-F4/80 and CD80 antibodies to quantify changes in M1like TAMs. Stained cells were analyzed with a Guava Easycyte system. The upper right quadrant
represents double positive macrophages (either F4/80+ CD206+ or F4/80+ CD80+ ). The lower right
quadrant represents macrophages (CD11b+ F4/80+ . The lower quadrant represents CD11b+ F4/80−
non-macrophage cells (e.g., tumor cells). Samples were pooled from 3-5 mice per group- one biological
replicate. 5000 cell counting events in each dot plot.
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3.4.2

Zymosan:Adenovirus Induces Immune Favorable Conditions in the
TME
The purpose for TAM reprogramming is to reverse the immunosuppression in the TME,

specifically to shift a Th2 to a Th1 immune profile. To explore the effects that Zym:Ad had on
the immune status of the TME, changes in cytokine and immune cell gene expression were quantified. The cytokine and chemokine composition of the TME is a partial indicator of anti-tumor
immune response. Th1 associated cytokines (TRAIL, IL-12, IFNγ) were upregulated and Th2 associated cytokines/chemokines (CXCL1, CXCL2, MIF) were downregulated (Figure 3.5A). TNF-related
apoptosis-inducing ligand (TRAIL) induces tumor cell death via NK cell activity [Lin et al., 2007].
TRAIL gene expression was upregulated in Zym:Ad IRF3 (4.7 times) and Zym:Ad IRF7 to a lesser
extent but not in Zym:Ad GFP treated tumors. IL-12, cytokine involved in T cell activation, gene
expression upregulated in all three Zym:Ad treatments with a more significant increase in Zym:Ad
IRF3 (17 times) treatment. IFNγ, indicator of T cell cytotoxicity, was upregulated in Zym:Ad
IRF7 and Zym:Ad IRF3 (3 times) but not in Zym:Ad GFP. CXCL1 in the TME is associated with
therapeutic resistance and tumor progression [Yu et al., 2020]. CXCL1 gene expression decreased
in Zym:Ad GFP (10 times) and Zym:Ad IRF3 (2.9 times). CXCL2 activates CXCR2 on TAMs
to induce an anti-inflammmatory pro-tumor phenotype [Han et al., 2019, Di Mitri et al., 2019].
CXCL2 decreased slightly in all three treatments with Zym:Ad. Macrophage migration inhibitory
factor (MIF) is expressed on most immune cells and has been implicated in immunosuppression in
several solid tumors [Noe and Mitchell, 2020]. MIF gene expression decreased in all three Zym:Ad
treated tumors with a 2 times more significant decrease in Zym:Ad IRF3 and Zym:Ad IRF7.
Insight into immune cell composition of the TME was determined by analyzing relative gene
expression of specific T cell markers (Figure 3.5B). Overall, there was a significant increase in CD3
expression in all three Zym:Ad treated tumors with the most significant upregulation in Zym:Ad
GFP treated tumors. CD4 expression increased significantly in Zym:Ad IRF3 and Zym:Ad IRF7.
Further, CD8 expression increased in all three Zym:Ad treated tumors with a significantly greater
increase in Zym:Ad GFP treated tumors. To gain insight into the activation status of these CD4 and
CD8 T cells, FoxP3, IFNγ, and IL-12 gene expression were analyzed (Figure 3.5C). FoxP3, marker of
regulatory CD4 T cells, expression was reduced in Zym:Ad IRF3 and Zym:Ad IRF7 treated tumors.
Two cytokines indicative of a Th1 immune response, IFNγ and IL-12, increased in response to all
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(A)

(B)

(C)

Figure 3.5: Zymosan:Adenovirus shifts treated tumors from an immunosuppressive toward an immune active TME. RNA was extracted from treated (right) tumor tissue homogenate
using Trizol and qRTPCR was performed to analyze relative gene expression using the DDCT
method. A. A heatmap was created using Log2 transformed relative gene expression values to compare cytokine/chemokine expression (Trail, IL-12, IFN-γ, CXCL1, CXCL2, MIF) in treated tumors
B. Relative gene expression bar graphs give insight into immune cell composition (CD3, CD4, CD8)
in treated tumors C. Relative gene expression bar graphs give insight into activation status for
CD4/CD8 T cells. Error bars indicate range of two technical duplicates. Samples were pooled from
3-5 mice per group- one biological replicate.
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three Zym:Ad treatments with the exception of IFNγ expression in Zym:Ad GFP treated tumors.
Of note, Zym:Ad IRF7 induced the most significant upregulation of IFNγ. The differences between
can be attributed to IRF3 directly promoting transcription of IL-12 [Jefferies, 2019] whereas IRF7
more directly promotes transcription of type I IFNs thus contributing to a greater increase in IFN-γ.
Preliminary data was collected to gain insight into the metabolic state of the TME, as it is
closely associated with immunotherapy efficacy and anti-tumor immune response [Luby and AlvesGuerra, 2021]. Relative gene expression of metabolic markers (Arg1, Aco2, Hif1α, iNOS, Irg1) in
tumor homogenate were analyzed (Figure 3.6). Arginase 1 (Arg1) encodes an enzyme that depletes
arginine in the TME. Arginine is essential for T cell proliferation and activation [Ananieva, 2015].
Tumors treated with all three Zym:Ad treatments had significantly downregulated expression of
Arg1 compared to the untreated control; however, there was no significant difference between GFP,
IRF3, and IRF7. ACO2, responsible for the break in the TCA cycle that leads to increased use
of glutamine and buildup of itaconate [Palmieri et al., 2020], gene expression was 10 times more
downregulated in tumors treated with Zym:Ad IRF3 compared to Zym:Ad GFP. IRG1, enzyme
involved in converting cis-aconitate to itaconate, was significantly upregulated in Zym:Ad IRF7 and
Zym:Ad IRF3 but not in Zym:Ad GFP. In addition, there was no change in HIF-1α and iNOS gene
expression for Zym:Ad IRF3 or Zym:Ad IRF7. Taken together, this data suggests that intratumoral
injection of Zym:Ad induced changes in metabolism, cytokine/chemokine expression, and immune
cell composition that could support a Th1 anti-tumor immune response.
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Figure 3.6: Zymosan:Adenovirus Alters Metabolic Gene Expression in Treated Tumors
RNA was extracted from treated (right) tumor tissue homogenate using Trizol and qRTPCR was
performed to analyze relative gene expression using the DDCT method. A. A heatmap was created
using Log2 transformed relative gene expression values to compare metabolic expression (Arg1,
Aco2, Hif1α, iNOS, Irg1) in treated tumors. Samples were pooled from 3-5 mice per group- one
biological replicate.
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3.4.3

Zymosan:Adenovirus Induces Systemic Tumor Immunity
A potent immunotherapy should induce systemic tumor immunity. In this study, two fac-

tors were used to assess systemic tumor immunity including analysis of the untreated (left) tumor
and splenocyte function. Zym:Ad IRF3 and Zym:Ad IRF7 significantly reduced tumor growth in
the untreated tumor compared to the untreated control, and Zym:Ad IRF3 reduced growth more
significantly than the Zym:Ad GFP treatment (Figure 3.7).

Figure 3.7: Systemic anti-tumor effects on untreated tumors Tumor volume growth curve on
the untreated (left) tumor calculated from tumor length and width measurements taken on days 10,
14, 21, and 29. Compared with control group, p<0.05; compared with Zym:Ad GFP treated group,
#p<0.05; N=5.
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Immune favorable conditions in terms of metabolism and cytokine/chemokine expression
were analyzed using the same genes and methods as in figures with the treated tumors. The trends
were similar with a more significant difference between Zym:Ad GFP and Zym:Ad IRF3 gene expression. Metabolic changes included a decrease in Arg1 and Aco2, increase in Irg1, and no change
in Hif1α and iNOS (Figure 3.8A). However, NO production increased in vitro following all three
Zym:Ad treatments (Figure 2.10). Cytokine/chemokine expression changes included an increase
in Trail, IL-12, and IFNγ, decrease in MIF, and no change in CXCL1 and CXCL2 (Figure 3.8B).
The macrophage signature in the untreated tumors indicated an increase in F4/80 and CD80 and
a decrease in CD206 and CD163 suggesting a shift from M2-like to M1-like (Figure 3.8C). Further,
untreated tumors in Zym:Ad treated mice had increased expression of CD3, CD4, and CD8 with a
similar trend as was seen in the treated tumors (Figure 3.8D).
To further evaluate a systemic tumor immune response, splenocyte proliferation in the
presence of B16 tumor cells was analyzed. Splenocytes were co-cultured with B16 cells at varying
effector to target ratios (40:1, 20:1, and 10:1). Percent specific lysis was calculated as described in
materials and methods and indicated that Zym:Ad treated mice had a significant increase in B16
lysis compared to the untreated control (Figure 3.8). Additionally, splenocyte lysis of tumor cells
was calculated in terms of lytic units per spleen to consider the nonlinearity of effector to target cell
lysis. Compared to untreated, control mice, lytic units per spleen increased in Zym:Ad GFP treated
mice (3.8 times) and Zym:Ad IRF3 (4.3 times) (Figure 3.9). Taken together, Zym:Ad GFP, Zym:Ad
IRF7, and Zym:Ad IRF3 induced a systemic anti-tumor immune response, but Zym:Ad IRF3 more
effectively reduced tumor growth in untreated tumors and thus had the most effective therapeutic
effect.
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(A)

(B)

(C)

(D)

Figure 3.8: Systemic tumor immunity is induced in untreated tumors. RNA was extracted
from untreated (left) tumor tissue homogenate using Trizol and qRTPCR was performed to analyze
relative gene expression using the DDCT method. A. A heatmap was created using Log2 transformed
relative gene expression values to compare metabolic expression (Arg1, Aco2, Hif1α, iNOS, Irg1)
in untreated tumors B. A heatmap was created using Log2 transformed relative gene expression
values to compare cytokine/chemokine expression (Trail, IL-12, IFNγ, CXCL1, CXCL2, MIF) in
untreated tumors C. Relative gene expression of macrophage marker (F4/80), M1 marker (CD80),
and M2 markers (CD163, CD206) were analyzed to gain insight into shift in TAM abundance and
phenotype in untreated tumors. D. Relative gene expression bar graphs give insight into immune
cell composition (CD3, CD4, CD8, FoxP3) in untreated tumors. Error bars indicate range of two
technical duplicates. Samples were pooled from 3-5 mice per group- one biological replicate.
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(B)

(A)

Figure 3.9: Splenocyte cytotoxicity suggests establishment of systemic tumor immunity.
Splenocytes harvested from inoculated mice co-cultured with B16 cells (40:1, 20:1, 10:1) were used in
a splenocyte proliferation assay A. Percent specific lysis was calculated as described in materials and
methods. Compared with control group p<0.001, p<0.01. Results displayed as +/- SD. Samples
pooled from 3-5 mice per group- one biological replicate. B. An alternative calculation considers
the nonlinearity of effector to target lysis of tumor cells. Thus, lytic units/spleen were calculated as
described in materials and methods. Compared with control group, p<0.05. Results displayed as
+/- SD.
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3.5

Discussion
This is the first study to date that has explored the immunotherapeutic effects of intratu-

morally injected zymosan-adenovirus conjugates. This in vivo study showed that Zym:Ad induced
upregulation of Th1 and downregulation of Th2 related gene expression in the TME through relative gene expression comparisons. Further, Zym:Ad induced a systemic tumor immune response
as determined by tumor growth and gene expression analysis of the untreated tumors as well as a
splenocyte proliferation assay. Lastly, tumor growth curves revealed a significant therapeutic benefit when Zym:Ad encoded constant active IRF3 indicating that IRF3 aids in additional anti-tumor
activity.
The double tumor model is a common model for IT immunomodulatory therapies and
was chosen specifically for this study to determine the potential of Zym:Ad to induce systemic
tumor immunity via IT injection. Historically, the efficacy of IT immunotherapies focused on direct
anti-tumor activity in treated tumors. Researchers have come to realize that the most effective
IT immunotherapies, and immunotherapies in general, induce a systemic tumor immune response
[Hong et al., 2020]. Systemic tumor immunity suggests that TILs primed in the TME by the
IT immunotherapy depart from the tumor tissue and induce expansion and activation of other
lymphocytes in nearby lymph nodes. These tumor-specific lymphocytes are sent into circulation
and can mount an anti-tumor response when they come into contact with tumor cells (primary or
metastatic). In summary, there are many ways to identify systemic tumor immunity (e.g., serum
analysis, lymph node analysis, double tumor models). Out of these approaches, the double tumor
model is the only functional measure of systemic tumor immunity making it an excellent model for
our study.
The phenotypic changes induced by Zym:Ad treatments in vitro translated to the changes
observed in vivo. M2-like gene expression was downregulated and M1-like gene expression was
upregulated. Since tumor tissue was analyzed as homogenate insight into immune cell distribution
throughout the TME was not assessed. Future analyses of TAMs should include some form of spatial
omics analysis to determine spatial distribution of M1-like and M2-like TAMs, as well as tumor
infiltrating lymphocytes (TILs) [Fu et al., 2021]. Immune cell distribution would allow for more
accurate determination of the type of immune TME (e.g., infiltrated, excluded, immune desert),
which in turn would give insight into efficacy of the immunotherapy. In this particular study it

80

would be helpful to determine if the increased expression of M1-like TAMs induced by the Zym:Ad
treatment is associated with M1 TAM accumulation in the core or in the periphery of the tumor.
The flow cytometric analysis of M1-like and M2-like TAMs indicated that there was an
increase in M1-like TAMs and a decrease in M2-like TAMs following Zym:Ad treatments. However
these percentages were quite small and warrant elaboration. The CD11b isolation kit was only 70%
effective in isolating CD11b+ cells, thus there were a significant number of cells in the lower left
quadrant of the flow cytometric plots (Figure 3.4), which contributed to the small percentages of
double positive cells in the upper right quadrants. Another note about this analysis involves the less
than ideal timing of harvesting tumor tissue. Tumor tissue was collected 8 days after the last IT
injection of Zym:Ad. The Zym:Ad treatment is designed to induce a temporary pro-inflammatory
immune response, thus 8 days after an injection a weakened pro-inflammatory response is to be
expected. The ideal analysis of changes in M1 and M2 TAM populations would be conducted two
to three days post IT injection to observe the most significant differences. Since the focus of this
study was on therapeutic effects and induction of systemic immunity there were not enough mice to
sacrifice early to perform the analysis at the ideal time. Nonetheless, the data still indicates a slight
shift in TAM phenotype in response to the Zym:Ad treatment.
The immune cell composition of the TME is prognostic of tumor progression and immunotherapy response. The increase in CD8 T cell expression is highly supportive of a shift from a
cold to hot TME. Further, the decrease in immunosuppressive IL-10 gene expression and increase in
Th1 related gene expression of TRAIL, IL-12 and IFNγ support T cell proliferation and activation.
A more robust analysis of the cytokine profile in the TME should be conducted in future studies
by isolating and analyzing tumor interstitial fluid [Celis et al., 2004]. The high CD3 expression in
Zym:Ad GFP compared to Zym:Ad IRF3 and the high CD4 expression in Zym:Ad IRF3 compared
to Zym:Ad GFP need to be further investigated to distinguish biological relevance. CD3 positive T
cells should be sorted and quantified by type and activation markers using multi-channel flow cytometry. Specifically, CD4 cells should be co-stained with FoxP3 and CD25 to represent regulatory
T cell population and IL-12R or IFNγR2 for Th1 helper T cells.
The data suggests that there could be noteworthy metabolic changes in the TME following
treatment with Zym:Ad IRF3. Irg1 expression was significantly upregulated, indicative of M1-like
metabolism. Along with the downregulation of Aco2, this data suggests that metabolic changes in
the TCA cycle were trending towards an M1-like state. Further, decreased Arg1 expression suggests
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that arginine metabolism is shifting away from the arginine-ornithine/urea pathway, thus potentially
creating a better metabolic environment for T cell proliferation and expansion. HIF-1α augments
immunosuppression in the TME by promoting immunosuppressive TAM function, infiltration of Th
17 cells, and inhibition of TIL effector functions [Kumar and Gabrilovich, 2014, You et al., 2021].
The results show no change in HIF-1α expression accompanied by a decrease in Th2 associated
gene expression and an increase in IFNγ, indicative of TIL effector activity (Figure 3.5) suggesting
that HIF-1α expression is not preventing immune activation in the TME. Although Arg1 expression
decreased, iNOS expression was unaltered suggesting that iNOS expression was already high or
the treated TAMs utilized an alternate preferred metabolic pathway. Results from our in vitro
experiments indicated that NO production in TAM-like BMDMs treated with Zym:Ad increased
prompting further investigation into metabolic changes induced by Zym:Ad (Supplemental Figure
2.10). In future studies, all of the gene expression analyses should be repeated at the protein level,
and metabolite levels in the TME, indicative of immune cell function, should also be quantified as
described in the next section [Li et al., 2021b].
As previously mentioned, the Zym:Ad particle itself induces a pro-inflammatory response
and therefore can be used in TAM reprogramming and inducing immune favorable conditions; however, our data indicated that the additional expression of constant active IRF3 made the treatment
more effective in terms of reducing tumor growth, both IT injected tumors and untreated tumors
in the same mice. 21 days after Zym:Ad intratumoral treatment, Zym:Ad GFP and Zym:Ad IRF3
appear to be equally as effective in reducing tumor growth. By 29 days, Zym:Ad IRF3 is significantly
more effective than Zym:Ad GFP suggesting that the Zym:Ad IRF3 treatment is more robust in eliciting a beneficial therapeutic effect. The divergence of the GFP and IRF3/IRF7 treatments by day
29 is not unexpected. Early anti-tumor response could be attributed to the Zymosan-Adenovirus
particle itself; however, IRF3 and IRF7 promote transcription of additional anti-tumor cytokine
production, such as type I IFNs that could contribute to the increased anti-tumor activity at Day
29. For this reason, future studies should include a longer in vivo study to observe this trend.
In vitro results supported the notion that Zym:Ad reprograms TAMs from M2-like to M1-like
and readily infects macrophages more than B16 cells. However, our data does not identify Zym:Ad
uptake in vivo. In this study, cell-specific uptake of GFP could not be analyzed because our gene
expression was transient and tissue was analyzed 8 days after the last injection. In future in vivo
studies, single cell suspension from tumor tissue should be analyzed 24-48 hours after injection using
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flow cytometry to analyze GFP+ cells. As a β-glucan, zymosan binds to and can be phagocytized
by dendritic cells, neutrophils, and macrophages and can activate NK cells and even T cells [Zhang
et al., 2018]. This study focused on phenotypic changes in macrophages; however, activation of
these other immune cells would also be advantageous in inducing immune favorable conditions and
the extent to which they play a role in this particle Zym:Ad conjugate particle uptake has yet to
be explored [Zhang et al., 2018]. Although zymosan should enhance uptake in phagocytic cells [Liu
et al., 2015], in vitro results suggest that a small fraction of Zym:Ad particles may be taken up by
B16 tumor cells. Uptake of IRF3 by tumor cells can induce apoptosis and additional anti-tumor
activity [Duguay et al., 2002]. Whether this anti-tumor activity is enough to accountant for the
difference in reduced tumor growth between Zym:Ad GFP and Zym:Ad IRF3 or Zym:Ad IRF7 is
unknown. This can be investigated through cytotoxic analysis of Zym:Ad GFP, Zym:Ad IRF3, or
Zym:Ad IRF7 infected B16 cells.
Intratumoral injections are becoming increasingly beneficial in solid tumors that can be
accessed percutaneously, during surgery, or other procedures (e.g., colonoscopy) [Marabelle et al.,
2018]. Direct tumor injection has the potential to induce a strong anti-tumor response with minimal off-target, systemic toxicity. Reduced systemic toxicity can be attributed to smaller drug
amounts and less accumulation of drugs in non-tumor tissue. The immunomodulatory use of the
Zymosan:Adenovirus conjugate particles is not limited to melanoma, rather it could have broader applications in other tumor types with immunosuppressive TMEs [Maleki Vareki, 2018]. This Zym:Ad
IRF3 treatment, in particular, should also be considered to enhance current immunotherapies, such
as checkpoint inhibitors and tumor peptide vaccines, as described in the following section.
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3.6

Supplementary Data

Figure 3.10: Relative Gene Expression gives insight into CD4/CD8 Activation in Untreated Tumor RNA was extracted from untreated (left) tumor tissue homogenate using Trizol
and qRTPCR was performed to analyze relative gene expression using the DDCT method. Relative
gene expression bar graphs give insight into immune cell status (FoxP3, IL-12, IFNγ) in untreated
tumors. Error bars indicate range of two technical duplicates. Samples were pooled from 3-5 mice
per group.
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Chapter 4

Conclusion and Future Directions
4.1

Conclusion
Zym:Ad was readily taken up by macrophages, induced upregulation of M1-like genes, cy-

tokines, and transcription factors and downregualtion of M2-like genes, cytokines, and transcription
factors in vitro. In vivo, Zym:Ad induced upregulation of immune favorable gene expression in the
TME. Further, Zym:Ad induced systemic tumor immune activity as determined by untreated tumor
growth analysis and splenocyte-B16 proliferation assay. The most significant difference in Zym:Ad
GFP, Zym:Ad IRF3, and Zym:Ad IRF7 was seen in the tumor growth curves. All three treatments
reduced tumor growth, however, Zym:Ad IRF3 was the most effective in reducing tumor growth.
This result, indicated that constant active IRF3 aided in anti-tumor activity; however, the mechanism is unknown. Taken together, the immunotherapeutic effects of Zym:Ad IRF3 prompts further
investigation in IT immunomodulatory combination therapies in melanoma and other solid tumors.

4.2
4.2.1

Future Directions
Investigate IT Immunomodulatory Combination Therapies
The combination of zymosan and adenovirus is a novel IT immunomodulatory therapy. The

observed induction of immune favorable conditions in the TME make Zym:Ad a promising candidate
for enhancing immune checkpoint inhibitors. Currently TLR agonists have been clinically approved
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as adjuvant therapies and have been pre-clinically and clinically tested in combination with immune
checkpoint inhibitors [Kaczanowska et al., 2013, Locy et al., 2018]. Two major challenges of TLR
agonists are their toxicity at high doses and their quick diffusion from injection site, both of which
can be overcome by the Zymosan:Adenovirus conjugate IT treatment. Although adenovirus can be
immunogenic it is not needed in high doses when conjugated to zymosan particles, and zymosan
particles are considered nontoxic and would likely not diffuse as quickly as small molecule TLR
agonists [Zhang et al., 2018]. Using the same double tumor B16 mouse model, Zym:Ad IRF3 and
TLR agonists should be compared in combination therapies with an immune checkpoint inhibitor.
The PD-1/PD-L1 receptor-ligand complex classically acts as a checkpoint to prevent autoimmune responses toward self antigens and cells. PD-L1 expression can be found on tumor cells,
macrophages, dendritic cells, and other self cells. Although some tumor cells do not express PD-L1,
this has not been shown to be as influential on ICI efficacy as compared to PD-L1 expression on
other immune cells [Lei et al., 2021]. In the TME, PD-L1 expression, on APCs and tumor cells,
plays a role in immunosuppression by binding to PD-1 on T cells, thus leading to their deactivation [Zheng et al., 2019]. Thus, treatments that prevent interaction of PD-1 and PD-L1, namely
anti-PD-1 or anti-PD-L1, can reduce immunosuppression, yet, immune checkpoint inhibitors alone
are rarely effective. Another contributing factor to ICI efficacy is the presence or absence of CD8
T cells in the TME. Most tumors tend to lack CD8 T cells and are immunosuppressive, rendering
these ICIs ineffective.
Based on the upregulation of CD8 gene expression we are interested in comparing Zym:Ad
IRF3 with TLR agonists in combination with anti-PD-1 immune checkpoint inhibition. We would
use the same double tumor model with a series of injections. In this case, we would inject the Zym:Ad
IRF3 or TLR agonist 24-48 hours before administering anti-PD-1. Since anti-PD-1 relies on tumor
infiltrating CD8 T cells, we would want to give the adjuvant enough time to alter the immune
status of the TME. The experimental groups would include anti-PD-1 alone, anti-PD-1 + Zym:Ad
IRF3, and anti-PD-1 + TLR agonist. We would analyze reduction in tumor growth, immune status
of injected and non-injected tumor, and induction of systemic tumor immunity as was done in this
study. Another measure of systemic tumor immunity that we would like to investigate is the immune
composition of the tumor draining lymph node (TDLN), either inguinal or axillary depending on
exact location of subcutaneous tumor, following an established protocol [Fransen et al., 2018]. The
immune status of the TDLN would give us more insight into activation of anti-tumor CD8 T cells
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following the intratumoral treatments.

4.2.2

Metabolomics in TAMs and the TME
Based on our findings regarding metabolic gene expression changes in TAMs in vitro and in

tumor tissue in vivo. We propose a future study focused on pro- and anti-tumor metabolic changes
induced by the zymosan:adenovirus conjugate particles. TAM metabolism is closely associated with
their phenotype and function.
Using the same in vitro experiment design, we would compare the OCR and the ECAR using
extracellular flux analysis [Weiss et al., 2018]. M1-like TAMs should display increased glycolysis as
indicated by ECAR and decreased OXPHOS as indicated by OCR compared to M2-like TAMs.
An increase in glycolysis drives an increase in reactive oxygen species (ROS) production; however
ROS production alone has been linked to M1 and M2 activation, thus the pro- and anti-tumor
effects of ROS seem to be context dependent [Kennel and Greten, 2021]. Nonetheless an increase in
glycolysis allows for quick energy turnover and intermediate metabolites that are needed to induce
a pro-inflammatory state [Galván-Peña and O’Neill, 2014]. Increased OXPHOS suggests an intact
TCA cycle, which is indicative of M2 macrophages [Diskin and Pålsson-McDermott, 2018]. TLR
agonists are typically involved in M1 polarization of macrophages; however not all TLR agonists
include the same metabolic changes. Zymosan is a TLR2 agonist and adenovirus is a TLR4 agonist.
In monocytes, TLR4 agonists have been shown to enhance glycolysis and reduce OXPHOS, but
TLR2 agonists did not induce the same trend [Liu et al., 2021]. IRF3 and IRF7 are two of the main
transcription factors activated through TLR4 stimulation, thus Zym:Ad IRF3 or Zym:Ad IRF7 may
induce metabolic differences when compared to Zym:Ad GFP.
There are significant differences in the TCA cycle in M1 and M2 macrophages. In this work,
gene expression of IRG1, ACO2, and HIF-1α gave insight into potential breaks in the TCA cycle
indicative of M1 polarization. IRG1, ACO2, and HIF-1α should be quantified at the protein level in
future studies. The breaks in the TCA cycle in M1 macrophages lead to accumulation of itaconate
and succinate. To further investigate these M1 metabolic changes, itaconate and succinate should
be quantified using liquid chromatography and mass spectrometry (LC-MS) [Tannahill et al., 2013].
Fatty acid metabolism should also be investigated. Specifically, lipid accumulation in TAMs
has been associated with tumor promotion. M2 macrophages have increased fatty acid oxidation
(FAO). Fatty acids activate nuclear receptors including peroxisome prolierator-activated receptors
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(PPARs) and other transcription factors involved in M2 polarization and pro-tumor functions [Li
et al., 2017b]. Fatty acid uptake should be quantified in TAMs with and without Zym:Ad treatment
[Su et al., 2020].
We propose to do an untargeted metabolomics analysis to get an overview of the metabolic
profile in the TME. This analysis should be conducted on homogenized tumor tissue using LC-MS
following a previously published protocol [Astarita et al., 2020]. Specific changes in the tryptophan/kynurenine pathway should be included. Tryptophan is needed for efficient T cell effector
function, thus its depletion by tumor cells in the TME contributes to immunosuppression [Van Baren
and Van den Eynde, 2015, Sorgdrager et al., 2019]. Additionally lactate and glucose levels should be
analyzed. Activated T cells utilize glucose as their main metabolic pathway. Lactate is a product of
glycolysis and thus lactate accumulation in the TME prevents T cells from releasing the lactate leading to reduced anti-tumor function. The high levels of lactate in the TME are typically attributed
to the Warburg effect in tumor cells [Renner et al., 2017]. In summary, we would want to determine
if the Zym:Ad treatment reduces lactate and increases tryptophan in the TME as an indicator of a
shift from immunosuppressive to an immune active TME.
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